Page last updated: 2024-08-24

topotecan and Ovarian Neoplasms

topotecan has been researched along with Ovarian Neoplasms in 405 studies

Research

Studies (405)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	65 (16.05)	18.2507
2000's	222 (54.81)	29.6817
2010's	107 (26.42)	24.3611
2020's	11 (2.72)	2.80

Authors

Authors	Studies
Besterman, JM; Croom, DK; Emerson, DL; Evans, MG; Lackey, K; Leitner, PL; Luzzio, MJ; McIntyre, G; Sternbach, DD; Vuong, A; Yates, J	1
de Jong, LA; Floot, BG; Maliepaard, M; Pluim, D; Ruevekamp-Helmers, MC; Schellens, JH; van Gastelen, MA; van Waardenburg, RC	1
Alloatti, D; Badaloni, E; Cabri, W; Castorina, M; Giannini, G; Pisano, C; Vesci, L	1
Choi, CH; Joung, JG; Kim, BG; Kim, HS; Kim, JW; Kim, S; Lee, JB; Lee, JY; Park, E	1
Januchowski, R; Jopek, K; Kaźmierczak, D; Nowicki, M; Rucinski, M; Stasiak, P	1
Arndt, T; Belau, AK; Braicu, EI; Canzler, U; Chekerov, R; de Gregorio, N; Mahner, S; Mustea, A; Neunhoeffer, T; Pietzner, K; Richter, R; Sehouli, J; Stocker, G; Strauß, HG; von Abel, E; Wimberger, P; Woelber, L; Yalinkaya, I	1
Kemmochi, S; Kimura, T; Makita-Suzuki, K; Matulonis, UA; Mori, M; Morohashi, Y; Nakayama, S; Okada, K; Shimoyama, S	1
Januchowski, R; Nowicki, M; Świerczewska, M; Wojtowicz, K	1
Bastière-Truchot, L; Berger, R; Berton-Rigaud, D; Cardona, A; Colombo, N; du Bois, A; González Martin, A; Greimel, E; Grischke, EM; Hilpert, F; Kroep, JR; Kurzeder, C; Lorusso, D; Lück, HJ; Martinez-Garcia, J; Mirza, MR; Ottevanger, P; Pardo, B; Rau, J; Redondo, A; Selle, F; Vergote, I	1
Bergamini, A; Bocciolone, L; Candiani, M; Fodor, A; Mangili, G	1
Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B	1
Jo, DY; Ko, YB; Lee, HJ; Lee, MW; Ryu, H; Song, IC; Yun, HJ	1
Aghajanian, C; Banerjee, S; Berger, R; Boyd, AP; Christy-Bittel, J; Churruca, C; Cibula, D; Clamp, A; Coleman, RL; Colombo, N; Del Campo, JM; Drill, E; Grisham, RN; Hilpert, F; Kalbacher, E; Kristensen, G; Marth, C; Mirza, MR; Monk, BJ; Moore, KN; O'Malley, DM; Oehler, MK; Oza, AM; Pignata, S; Ray-Coquard, I; Romero, I; Sehouli, J; Vergote, I; Vuylsteke, P; Westermann, A	1
Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS	1
Brajanovski, N; Chan, KT; Cullinane, C; Ellis, S; Hannan, KM; Hannan, RD; Kang, J; Madhamshettiwar, PB; Pearson, RB; Sanij, E; Sheppard, KE; Simpson, KJ; Tancock, MRC; Xuan, J; Yan, S	1
Alexandre, J; Berton-Rigaud, D; Bohan, P; Casado, A; Del Campo, JM; Fernández Teruel, C; Fernández, C; Galmarini, CM; Gonzalez-Martin, A; Guerra Alía, EM; Kahatt, C; Pérez de la Haza, A; Poveda, A; Provansal, M; Ray-Coquard, I; Rodriguez, I; Soto, A	1
Brązert, M; Januchowski, R; Klejewski, A; Nowicki, M; Świerczewska, M; Zabel, M; Zaorska, K	1
Bonnetain, F; de la Motte Rouge, T; Kalbacher, E; Lesoin, A; Pautier, P	1
Murai, J	1
Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U	1
Brązert, M; Iżycki, D; Januchowski, R; Klejewski, A; Nowicki, M; Świerczewska, M; Wojtowicz, K; Zabel, M	1
Bauer, F; Rao, V; Vredenburgh, JJ	1
Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T	1
Corrado, G; Ferrandina, G	1
Braicu, EI; Chekerov, R; De Gregorio, N; du Bois, A; El-Balat, A; Fridrich, C; Harter, P; Hilpert, F; Krabisch, P; Lorenz, R; Lueck, HJ; Mahner, S; Markmann, S; Oskay-Oezcelik, G; Potenberg, J; Richter, R; Schmidt, M; Sehouli, J	1
Hjortkjær, M; Jakobsen, A; Kanstrup, H; Steffensen, KD	1
Andrzejewska, M; Brązert, J; Januchowski, R; Kędzia, W; Klejewski, A; Nowicki, M; Rusek, D; Sobkowski, M; Sterzyńska, K; Świerczewska, M; Wojtowicz, K	1
Choi, MC; Jeong, DH; Kang, S; Kim, JW; Kim, KH; Kim, TH; Kim, YB; Kim, YM; Lee, IH; Lee, JW; Lee, JY; Lee, KB; Lee, YJ; Park, JY; Park, SY; Pujade-Lauraine, E	1
Andrzejewska, M; Brązert, J; Brązert, M; Januchowski, R; Kaźmierczak, D; Klejewski, A; Nowacka, M; Nowicki, M; Rusek, D; Sterzyńska, K; Świerczewska, M; Wojtowicz, K	1
Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Kouroussis, C; Polyzos, A; Syrios, J; Vardakis, N	1
du Bois, A; Harter, P; Hedderich, J; Heilmann, T; Hempel, AM; Hilpert, F; Pfisterer, J; Pujade-Lauraine, E; Saß, S	1
Burger, RA; Fruehauf, JP; Kim, JH; Parmakhtiar, B	1
Fekete, JT; Győrffy, B; Menyhárt, O	1
Braicu, EI; Canaz, E; Chekerov, R; Grabowski, JP; Richter, R; Sehouli, J	1
Ahmad, M; Akhlaq, M; Danish, Z; Saeed, H; Saleem, Z; Sattar, S	1
Asher, R; Friedlander, M; Gebski, V; Gonzalez-Martin, A; Hardy-Bessard, AC; Hilpert, F; Kaminsky, MC; Kurzeder, C; Largillier, R; Lee, CK; Lesoin, A; Lortholary, A; Poveda, A; Pujade-Lauraine, E	1
Alavi, S; Chekerov, R; Inci, G; Richter, R; Sehouli, J; Woopen, H	1
Atlas, I; Barak, F; Berman, T; Bruchim, I; Levy, T; Meirovitz, M; Rosengarten, OS; Safra, T; Yachnin, A	1
Flatten, KS; Huehls, AM; Huntoon, CJ; Karnitz, LM; Kaufmann, SH; Sutor, SL; Wahner Hendrickson, AE	1
Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Richardson, DL; Salani, R; Smith, B	1
Anderson, L; Chalukya, M; Dandekar, S; Dering, J; Ginther, C; Ihnen, M; Jänicke, F; Jones, S; Kolarova, T; Konecny, GE; Los, G; Manivong, K; Meuter, A; Qi, JW; Rong, HM; Slamon, DJ; Udar, N; Velculescu, VE; Venkatesan, N; Winterhoff, B; zu Eulenburg, C	1
Curtin, J; Downey, A; Edwards, S; Kwa, M; Muggia, F; Reich, E; Wallach, R	1
Blank, SV; Curtin, J; Guddati, AK; Hochster, HS; Ivy, P; Joseph, B; Levinson, B; Muggia, F; Pothuri, B; Shapira, I; Stein, SM; Tiersten, A	1
Downey, A; Levinson, B; Liebes, L; Muggia, F; Tiersten, A; Warner, E	1
Banville, M; Collins, C; Cruz-Muñoz, W; Di Desidero, T; Hashimoto, K; Jaramillo, ML; Kerbel, RS; Man, S; O'Connor-McCourt, MD; Xu, P	1
Bamias, A; Bollag, D; Follana, P; Hilpert, F; Kristensen, G; Mirza, MR; Oaknin, A; Pereira, D; Poveda, A; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Sorio, R; Vergote, I; Weber, B; Wimberger, P; Witteveen, P	1
Barron, R; Chandler, DB; Fust, K; Li, X; Lyman, GH; Maschio, M; Parthan, A; Walli-Attaei, M; Weinstein, MC	1
Arranz, JA; de Gregorio, N; Freudensprung, U; Friedlander, M; Hales, G; Hilpert, F; Joly, F; King, MT; Lee, CK; Mirza, MR; Pujade-Lauraine, E; Sneller, V; Sorio, R; Stockler, MR; Wenzel, L	1
Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T	1
Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q	1
Morikawa, A; Nagata, C; Okamoto, A; Saito, M; Suzuki, J; Suzuki, K; Takahashi, K; Takakura, S; Tanabe, H; Yanaihara, N	1
Adewoye, H; Ananda, S; Bass, MB; Dirix, L; Gordon, AN; Kridelka, F; Leach, JW; Litten, J; Melara, R; Nanayakkara, N; Pippitt, CH; Schilder, RJ; Scudder, S; Vergote, I; Wenham, RM; Wong, S	1
Alosh, M; Huque, MF; Koch, GG	1
Barton, S; Edwards, SJ; Thurgar, E; Trevor, N	1
Chang Chien, CC; Fu, HC; Hu, CF; Lin, H; Ou, YC; Tsai, CC; Wu, CH	1
Matsumoto, K; Onda, T; Yaegashi, N	1
Gedroyc, W; Gonitel, R; Miller, AD; Rosca, EV; Thanou, M; Wright, M	1
Annunziata, CM; James, J; Kim, MK	1
Du, XL; Li, L; Shan, CP; Sheng, XG; Wei, P; Zhang, ZH	1
Jain, A; Jain, SK	1
Bevis, KS; Blansit, K; Chan, JK; ElNaggar, A; Fuh, KC; Huh, W; Kapp, DS; Previs, R; Secord, AA; Tillmanns, T	1
Ariyoshi, K; Nagayama, R; Okadome, M; Saito, T; Shimada, T; Shimamoto, K; Yamaguchi, S	1
Gjerset, RA; Zhao, M	1
Bamias, A; Hilpert, F; Mitchell, L; Poveda, AM; Pujade-Lauraine, E; Reuss, A; Savarese, A; Scotto, N; Selle, F; Vergote, I; Witteveen, P	1
Devriese, LA; Giantonio, BJ; Kerklaan, BM; Lane, S; Langenberg, M; Legenne, P; Lolkema, MP; Mergui-Roelvink, M; Mykulowycz, K; Nol-Boekel, A; Schellens, JH; Smith, DA; Stoebenau, J; Voest, EE; Wissel, P; Witteveen, PO	1
Brotto, L; Brundage, M; Casado, HA; Cervantes, A; Eisenhauer, E; Hoskins, P; Poveda, A; Tu, D; Vergote, I	1
Januchowski, R; Nowicki, M; Wojtowicz, K; Zabel, M	1
Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB	1
Armaiz-Pena, GN; Coleman, RL; Dalton, HJ; Davis, AN; Hansen, JM; Langley, RR; Lin, YG; Merritt, WM; Nick, AM; Pradeep, S; Previs, RA; Sood, AK	1
Fabbro, M; Gligorov, J; Lhommé, C; Lokiec, F; Lotz, JP; Pautier, P; Provent, S; Richard, S; Selle, F; Soares, DG; Viens, P	1
Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H	1
du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A	1
Hanvoravongchai, P; Havanond, P; Khempech, N; Luealon, P; Vasuratna, A	1
Ben-Harim, Z; Bruchim, I; Fishman, A; Haran, G; Piura, E	1
Anttila, M; Breda, E; Hanker, LC; Husain, A; Ojeda, B; Pujade-Lauraine, E; Vuylsteke, P; Wang, Y	1
Bastiere-Truchot, L; Berton-Rigaud, D; Colombo, N; Del Campo, JM; du Bois, A; Gadducci, A; García, Y; González-Martín, A; Kiermaier, A; Kurzeder, C; Mahner, S; Marmé, F; Martin, N; Ortega, E; Ottevanger, P; Pautier, P; Rau, J; Selle, F	1
Larson, RS; Lovato, DM; Ricci, JW; Severns, V; Sklar, LA	1
Belau, AK; Bover-Barcelo, I; Canzler, U; Chekerov, R; Gonzalez-Martin, A; Hanker, LC; Harter, P; Hilpert, F; Keil, E; Klare, P; Kurzeder, C; Mahner, S; Meier, W; Petru, E; Reinthaller, A; Richter, R; Sehouli, J; Wimberger, P; Woopen, H; Zeimet, A	1
Coeffic, D; García, Y; Gebski, V; Gibbs, E; González-Martín, A; Hilpert, F; Huizing, M; Kaern, J; Kristensen, G; Lee, CK; Levaché, CB; Lück, HJ; Pujade-Lauraine, E; Roemer-Becuwe, C; Sorio, R; Witteveen, P; Zagouri, F	1
Malpass, TW; McGonigle, KF; Muntz, HG; Robertson, MD; Weiden, PL	1
Goff, BA; Holmberg, LA; Kurland, BF; Veljovich, D	1
Camara, O; Keil, E; Klare, P; Lichtenegger, W; Oskay-Oezcelik, G; Paulenz, A; Sehouli, J; Sommer, H; Stauch, M; Stengel, D; Zeimet, AG	1
Eisenkop, SM; McAlpine, JN; Spirtos, NM	1
Coleman, RL; Gibb, RK; Herzog, TJ; Lippmann, L; Mutch, DG; Powell, MA; Rader, JS	1
Fusco, N; Haba, P; Rodriguez, M; Rose, PG; Smrekar, M	1
Bodnar, L; Gasowska-Bodnar, A; Nasilowska, A; Smoter, M; Szarlej-Wcislo, K; Szczylik, C; Wcislo, G	1
Hoskins, PJ	1
Accario-Winslow, C; Alberts, DS; Argenta, PA; Bookman, MA; Brady, MF; Burger, RA; Colombo, N; De Geest, K; Fowler, JM; Friedlander, M; Harper, PG; McGuire, WP; Mutch, DG; Roth, LM; Swart, AM; Trimble, EL	1
Oskay-Ozcelik, G; Sehouli, J	1
Apte, S; Boren, T; Chan, G; Chen, DT; Dressman, H; Hakam, A; Kamath, SG; Lancaster, JM; Wenham, R; Xiong, Y	1
Einstein, MH; Goldberg, GL; Gupta, D; Huang, GS; Kim, M; Kuo, DY; Owers, RL; Shahabi, S	1
Angioli, R; Arrivi, C; Basile, S; Bellati, F; Calcagno, M; Palaia, I; Panici, PB; Pastore, M; Plotti, F; Sansone, M	1
Chekerov, R; Fotopoulou, C; Karavas, A; Lichtenegger, W; Sehouli, J; Trappe, R	1
du Bois, A; Gropp, M; Kimmig, R; Kuhn, W; Lück, HJ; Meier, W; Olbricht, S; Pfisterer, J; Reuss, A; Richter, B	1
Bae, DS; Choi, CH; Kang, H; Kim, BG; Kim, TJ; Lee, JW; Lee, YY	1
Brown, G; del Campo, J; Finkler, N; Hunter, J; Jones, M; Kavanagh, J; Kaye, S; Lohr, A; Matei, D; Meng, L; Vergote, I; Vermorken, JB	1
Animati, F; Bellarosa, D; Bigioni, M; Binaschi, M; Bressan, A; Bugianesi, R; Crea, A; Maggi, CA; Manzini, S; Parlani, M; Rivoltini, L	1
Ames, MM; Ansell, SM; Barrette, BA; Dispenzieri, A; Elliott, MA; Frost, MH; Gastineau, DA; Gertz, MA; Hartmann, LC; Inwards, DJ; Kaufmann, SH; Keeney, GL; Lacy, MQ; Lingle, WL; Litzow, MR; Long, HJ; Micallef, IN; Peethambaram, PP; Porrata, LF; Reid, JM; Safgren, SL; Suman, VJ	1
Chen, XJ; Yang, JH; Zheng, W	1
Chandra, J; Coleman, RL; Danes, CG; Gershenson, DM; Han, LY; Jaffe, RB; Kamat, AA; Kim, HS; Lin, YG; Mangala, LS; Merritt, WM; Nick, AM; Shahzad, MM; Sood, AK; Spannuth, WA; Stone, RL	1
Bourgeois, H; Chevalier-Place, A; Delva, R; Guardiola, E; Henry-Amar, M; Joly, F; Mayer, F; Pautier, P; Petit, T; Sevin, E	1
Markman, M	4
Leath, CA; Phippen, NT	1
Chung, HH; Kang, S; Kang, SB; Kim, HS; Kim, JW; Park, NH; Seo, SS; Song, YS	1
Carroll, AR; Coleman, RL; Dumble, M; Jennings, N; Kamat, AA; Kumar, R; Lin, YG; Lu, C; Matsuo, K; Merritt, WM; Nick, AM; Shahzad, MM; Sood, AK; Spannuth, WA; Stone, RL; Zhang, S	1
Cruz-Munoz, W; Hashimoto, K; Kerbel, RS; Kumar, R; Man, S; Tang, T; Xu, P	1
Alvarez, RD; Bryant, CS; Deppe, G; Kumar, S; Morris, RT; Munkarah, AR; Shah, JP; Spannuth, W	1
Aimone, PD; Bolis, G; Danese, S; Lo Russo, D; Mangili, G; Raspagliesi, F; Scambia, G; Scarfone, G; Scollo, P; Villa, A	1
Cree, IA; Gabriel, FG; Glaysher, S; Johnson, P; Knight, LA; Narayanan, A; Parker, K; Polak, M; Poole, M	1
Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J	1
Fujioka, S; Kanemura, M; Kawaguchi, H; Ohmichi, M; Sasaki, H; Sekijima, T; Tanabe, A; Tanaka, Y; Terai, Y; Tsunetoh, S; Yamashita, Y	1
McGuire, WP	2
Brotto, L; Casado, A; Cervantes, A; Chen, D; D'Hondt, V; Eisenhauer, EA; Elit, L; Germa, JR; Ghatage, P; Grimshaw, R; Hoskins, P; Katsaros, D; Mendiola, C; Ojeda, B; Oza, A; Poveda, A; Provencher, D; Roy, M; Stuart, G; Sugimoto, A; Tu, D; Vergote, I; Zola, P	1
Aoki, D; Fujiwara, K; Hatae, M; Hiura, M; Kamiura, S; Katsumata, N; Kigawa, J; Nakanishi, T; Noda, K; Ochiai, K; Sugiyama, T; Takehara, K	1
Hartney, J; Lane, S; Legenne, P; Monk, BJ; Provencher, D; Rose, PG	1
Andreopoulou, E; Blank, S; Chen, T; Curtin, J; Hochster, H; Liebes, L; Muggia, F; Wallach, R	1
Belau, A; Bogenrieder, T; Doering, G; Harter, P; Kurzeder, C; Kuznik, A; Lichtenegger, W; Lorenz, R; Mahner, S; Markmann, S; Meerpohl, HG; Mueller, L; Nugent, A; Oskay-Oezcelik, G; Schroeder, W; Sehouli, J; Sommer, H; Stengel, D; Wilke, J; Wischnik, A	1
DeBernardo, RL; DeGeest, K; Herzog, TJ; Lentz, SS; Mutch, D; O'Malley, D; Shahin, M; Sill, MW; Walker, JL; Weiner, SA	1
Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D	1
Amin, MS; Eisenhauer, EA; Hoskins, PJ; Islam, S; O'Brien, AM; Pelletier, LB; Squire, JA; Tu, D; Weberpals, JI	1
Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A	1
Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C	1
Dakhilm, SR; Haluska, P; Hartmann, LC; Keeney, GL; Moore, DF; Oberg, AL; Peethambaram, PP; Rowland, KM; Weroha, SJ; Ziegler, KL	1
Carter, JS; Downs, LS	1
Alexandre, J; Dauba, J; Durando, X; Gladieff, L; Largillier, R; Lortholary, A; Paraiso, D; Pujade-Lauraine, E; Slama, B; Weber, B	1
Camporeale, A; Cormio, G; De Mitri, P; Gissi, F; Leone, L; Loizzi, V; Putignano, G; Selvaggi, L	1
Goff, BA; Gray, HJ; Greer, BE; Malpass, TW; McGonigle, KF; Muntz, HG; Paley, PJ; Veljovich, DS; Vuky, J	1
Arnold, AG; Grisham, RN; Hyman, DM; Iasonos, A; Kauff, ND; Spriggs, D; Zhou, Q	1
Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C	1
Ambrosone, CB; Armstrong, DK; Bookman, MA; Darcy, KM; Davis, W; DeLoia, JA; Gallion, H; Krivak, TC; Moysich, K; Tian, C; Zhao, H	1
Dorigo, O; Eng, C; Fekete, M; Santiskulvong, C	1
Bookman, MA	5
Jia, L; Kong, B; Li, D; Xu, Y; Zhang, H; Zhou, XC	1
DeBernardo, RL; Eaton, SM; Frasure, HE; Fusco, NL; Heugel, AM; Smith, DA; von Gruenigen, VE; Waggoner, SE	1
Accarpio, F; Benedetti-Panici, P; Bernabei, M; Biffoni, M; Casorelli, A; Di Donato, V; Di Giorgio, A; Pasquini, L; Petrucci, E; Saulle, E; Sibio, S; Testa, U	1
Anantha, M; Bally, MB; Patankar, NA; Strutt, D; Waterhouse, D	1
Barash, I; Baumgartner, R; Blank, S; Curtin, JP; Gabizon, A; Kopolovic, J; Kwa, M; Michael, J; Muggia, F; Puzanov, I; Rosengarten, O; Shavit, L	1
Arcand, SL; Caceres, KY; Cyr, L; de Ladurantaye, M; Delvoye, N; Létourneau, IJ; Mes-Masson, AM; Meunier, L; Portelance, L; Provencher, DM; Quinn, MC; Shen, Z; Tonin, PN; Wang, LL	1
Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B	1
Katsumata, N; Maejima, A	1
Kitao, A; Matsumoto, K	1
Bally, MB; Osooly, M; Patankar, NA; Pritchard, J; van Grinsven, M	1
Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH	1
Allott, CP; Boxall, FE; Kelland, LR; Rogers, P; Stephens, TC	1
Rowinsky, EK	1
Goldwasser, F; Gross-Goupil, M; Hasbini, A; Lokiec, F; Lopez, G; Misset, JL; Romain, D; Tigaud, JM	1
Beshara, N; Faught, W; Fung Kee Fung, M	1
Aydin, F; Canturk, T; Senturk, N; Turanli, AY; Yanik, F; Yildiz, L	1
Herzog, TJ	3
Morris, R; Munkarah, A	1
Coleman, RL	1
Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C	2
Adams, JR; Bennett, CL; Drummond, MF; Gordon, A; Johnston, SR; Smith, DH	1
Blohmer, J; Camara, O; Elling, D; Heinrich, G; Hindenburg, HJ; Klare, P; Ledwon, P; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D	1
Gutierrez, M; Lhomme, C; Pautier, P	1
Bian, ML; Cui, Y; Guan, ZZ; Huang, CJ; Li, JD; Liu, FY; Liu, JH; Song, L; Xin, XY; Zhou, QH	1
Benigno, B; Homesley, H; Vaccarello, L; Williams, J	1
Brown, JV; Drescher, CW; Graham, CL; Micha, JP; Peters, WA; Rettenmaier, MA; Smith, MR	1
Fields, AL; Runowicz, CD	1
Astre, C; Boucaud, M; Bressolle, F; Culine, S; Gomeni, R; Pinguet, F; Poujol, S	1
Gabryś, M; Gerber, J; Goluda, M; Jedryka, M	1
Chan, S	1
Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D	2
Balat, O; Ugur, MG	1
Capri, S; Cattaneo, G	1
Bookman, M; Copeland, LJ; Trimble, E	1
Casado, A; Casado, MA; de Sande, LM; Merino, P; Ojeda, B	1
Stuart, GC	1
Morris, RT	1
Spriggs, D	1
Herzog, TJ; Holloway, RW; Stuart, GC	1
Bukowski, R; Canetta, R; Ganapathi, R; Grabowski, D; Lee, F; Markman, M; Mekhail, T; Peck, R; Takigawa, N; Uyar, D	1
Blessing, JA; Lentz, SS; McMeekin, DS; Miller, DS	1
Bastien, L; De Jager, R; Duggal, A; Hu, W; Kavanagh, JJ; Kudelka, AP; Loyer, E; Verschraegen, CF; Vincent, M	1
Berkowitz, R; Campos, S; Colella, T; Duska, L; Fuller, A; Gore, S; Lee, H; Matulonis, U; Roche, M; Seiden, MV	1
Lane, SR; Ross, GA; ten Bokkel Huinink, W	1
Gao, QL; Jia, P; Liao, GN; Lu, YP; Ma, D; Wu, MF; Wu, SB; Xu, Q	1
Liu, SL; Peng, ZL; Qian, XL	1
Adams, JR; Armitage, JO; Bennett, CL; Demetri, GD; Elting, LS; George, JN; Lembersky, BC; Lyman, GH	1
Durand-Zaleski, I; Girre, V; Pujade-Lauraine, E	1
Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C; Høgdall, EV	1
Armstrong, DK	1
Agarwal, R; Foster, T; Guppy, AE; Nelstrop, AE; Rustin, GJ; Seckl, MJ	1
Ali, K; Fung, MF; Hopkins, L; Le, T; Leis, A; Pahwa, P; Reeder, B; Wright, K	1
Pfisterer, J	1
Almadrones, LA	1
Aghajanian, C; Ben-Porat, L; Chi, DS; Hensley, ML; Hoppe, B; Prasad, M; Sabbatini, P	1
Astrow, A; Barrett, E; Campos, S; Matulonis, U; Muggia, F; Roche, M; Rusk, J; Seiden, MV; Sivret, J	1
Branduardi, D; D'Incalci, M; Lupi, M; Matera, G; Ubezio, P	1
Brema, F; Chiara, S; Di Costanzo, G; Folco, U; Pastrone, I; Pronzato, P; Tognoni, A; Tomasello, L	1
Christodoulou, C; Deliyiannis, F; Malamos, NA; Rigatos, SK; Skarlos, DV; Stathopoulos, GP; Stathopoulos, JG	1
Jia, P; Li, F; Liao, GN; Lu, YP; Ma, D; Wu, MF; Wu, SB; Xu, Q	1
Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K	2
Biamonte, R; Cartenì, G; Danese, S; De Laurentiis, M; De Matteis, A; De Placido, S; Di Vagno, G; Febbraro, A; Gallo, C; Gasparini, G; Greggi, S; Lauria, R; Lombardi, AV; Manzione, L; Marinaccio, M; Naglieri, E; Perrone, F; Pignata, S; Scambia, G; Valerio, MR	1
Gibb, RK; Herzog, TJ; Horowitz, NS; Hua, J; Mutch, DG	1
Haller, G; Horak, P; Krainer, M; Pils, D; Pribill, I; Rössler, M; Tomek, S; Zielinski, CC	1
Christensen, IJ; Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C	1
Asmar, L; Bailey, CL; Gordon, AN; Messing, MJ; Pippitt, CH; Savage, J; Street, DG; Young, JA	1
Apolone, G; Buda, A	1
Gordon, AN; Rackoff, W; Sun, S; Tonda, M	1
Buller, RE; Geisler, JP; Lush, R; Sanders, L; Shahin, MS; Sood, AK; Sorosky, JI; Sullivan, D	1
Bjornsti, MA; de Jong, LA; Jansen, LE; Pluim, D; Schellens, JH; van Eijndhoven, MA; van Waardenburg, RC; Verseyden, C	1
Ahmad, T; Gore, M	1
Lupi, M; Matera, G; Ubezio, P	1
Johnston, SR	1
Alvarez, RD; Bhoola, SM; Bryant, C; Coleman, RL; Estes, JM; Herzog, T; Morris, R	1
Glezerman, M; Grisaru, D; Inbar, M; Levy, T; Menczer, J; Safra, T	1
Bookman, MA; Gallo, JM; Guo, P; Li, S; Ma, J; Orlansky, A; Pulfer, S; Vicini, P; Zhou, F	1
Anand, A; Chan, SY	1
Baki, M; Bodoky, G; Cseh, J; Csejtei, A; Csömör, S; Dank, M; Erfán, J; Esik, O; Faluhelyi, Z; Hernádi, Z; Izsó, J; Kammerer, K; Kásler, M; Krommer, K; Magyar, T; Mayer, A; Megyery, E; Moskovits, K; Pécsi, L; Pikó, B; Pintér, T; Pulay, T; Ruzsa, A; Szánthó, A; Szántó, I; Szántó, J; Szucs, M; Tálos, Z; Thurzó, L	1
Choi, M; Fogoros, S; Griffith, KA; Hu, YY; Liu, JR; Lucas, PC; Williams, J	1
Engelholm, SA; Gronlund, B; Horvath, G; Mäenpää, J; Ridderheim, M	1
Baykal, C; Baykal, Y; Ozer, S; Tulunay, G	1
Beijnen, JH; Bos, AM; De Vos, FY; de Vries, EG; Gietema, JA; Mourits, MJ; Rosing, H; van der Zee, AG; Willemse, PH	1
Altundag, K; Altundag, O; Gunduz, M; Morandi, P	1
Burger, H; Figg, WD; Gelderblom, H; Loos, WJ; Nooter, K; Sissung, TM; Sparreboom, A; Verweij, J	1
Braybrooke, JP; Davies, SL; Echeta, C; Flanagan, E; Ganesan, TS; Hickson, ID; Joel, S; Levitt, NC; Madhusudan, S; Propper, DJ; Te Poele, R	1
Azodi, M; Kelly, M; Makkenchery, A; McAlpine, J; O'Malley, DM; Rutherford, T; Schwartz, P; Tangir, J	1
Berman, ML; Burger, RA; Disaia, PJ; Fruehauf, JP; Kyshtoobayeva, AS; Manetta, A; Mehta, RS; Monk, BJ; Tewari, KS; Yu, IR	1
Burges, A; du Bois, A; Gropp, M; Harter, P; Huober, J; Pfisterer, J; Schade-Brittinger, C; Schmalfeldt, B; Staehle, A; Wollschlaeger, K	1
Beeler, JF; Haba, P; Rose, PG; Smrekar, M; Visser, C	1
Curtin, JP; Dellenbaugh, C; Hamilton, A; Hochster, H; Lee, S; Liebes, L; Mirchandani, D; Muggia, FM; Sorich, J; Yee, H	1
Ditto, A; Fanfani, F; Luoni, C; Mariani, L; Oggionni, M; Pilotti, S; Scambia, G; Suardi, S; Zunino, F	1
Chen, MD; Fleming, GF; Horowitz, I; Mitchell, S	1
Duska, L; He, X; Klein, A; Mallett, A; Roche, M; Seiden, MV; Supko, JG	1
Akman, L; Dikmen, Y; Goker, E; Karabulut, B; Ozsaran, A; Sanli, UA; Sezgin, C; Terek, MC; Uslu, R	1
Armstrong, DK; Lane, S; Levin, J; Poulin, R; Spriggs, D	1
Penson, RT; Seiden, MV	1
Goldberg, G; Hochster, HS; Mandeli, J; Muggia, F; Plimack, ER; Runowicz, C; Speyer, J; Wadler, S; Wallach, R	1
Brown, S; Chen, EX; Dancey, JE; Hirte, HW; Hotte, SJ; Moore, M; Oza, A; Pond, GR; Winquist, EW	1
Belinson, JL; Michener, CM	1
Burnett, A; Edwards, S; Facio, G; Garcia, AA; Muderspach, L; O'meara, A; Roman, L	1
Biamonte, R; Cartenì, G; Colucci, G; Danese, S; de Matteis, A; De Placido, S; Di Maio, M; Di Vagno, G; Febbraro, A; Gasparini, G; Lombardi, AV; Manzione, L; Marinaccio, M; Massidda, B; Nardi, M; Perrone, F; Pignata, S; Pisano, C; Scambia, G; Valerio, MR	1
Bell, JG; Fusco, NL; Markman, M; Rose, PG	1
Fan, SM; Feng, YJ; Yao, M; Yi, XF	1
Boissonneault, G; Laberge, RM; Lehoux, J; Lussier, S; St-Amant, C	1
Cailliot, C; Dosquet, C; Fabbro, M; Genève, J; Gligorov, J; Goetschel, A; Gosse, B; Lefèvre, G; Lhommé, C; Lokiec, F; Lotz, JP; Micléa, JM; Pautier, P; Provent, S; Ribrag, V; Selle, F; Viens, P; Viret, F	1
Barbieri, M; Bojke, L; Griffin, S; Main, C; Mather, L; Norman, G; Palmer, S; Riemsma, R; Stark, D	1
Bookman, MA; Fracasso, PM; McMeekin, DS	1
Coleman, RL; Gibb, RK; Gossner, G; Herzog, TJ; Horowitz, NS; Mutch, DG; Powell, MA; Rader, JS	1
Bădulescu, A; Bădulescu, F; Popescu, CF; Schenker, M; Stoica, Z	1
Economopoulos, T; Pectasides, D; Pectasides, M; Psyrri, A	1
Gibb, R; Herzog, TJ; Mutch, DG; Powell, MA; Rader, JS	1
Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM	1
Blohmer, JU; Bourgeois, H; Costa, S; du Bois, A; Geay, JF; Hardy-Bessard, AC; Jackisch, C; Kimmig, R; Kuhn, W; Lortholary, A; Lück, HJ; Meden, H; Meier, W; Möbus, V; Nitz, U; Olbricht, S; Pfisterer, J; Pujade-Lauraine, E; Quaas, J; Reuss, A; Richter, B; Schröder, W; Stähle, A; Wagner, U; Weber, B	1
Bernstein, S; Bidus, MA; Chernofsky, MR; Elkas, JC; Rose, GS; Sunde, J; Winter, WE	1
Alvarez, RD; Austin, JM; Barnes, MN; Davidson, SA; Huh, WK; Kilgore, LC; Leath, CA; Partridge, EE; Spannuth, WA	1
Grønlund, B	1
Aravantinos, G; Christodoulou, Ch; Malamos, NA; Rigatos, S; Skarlos, D; Stathopoulos, GP; Stathopoulos, J	1
Canales Ugarte, S; Cassinello Espinosa, J	1
Garst, J	1
Barter, J; Coleman, RL; Gordon, A; Herzog, TJ; Rackoff, W; Sun, S	1
Bernstein, R; Golan, A; Grisaru, D; Inbar, MJ; Levy, T; Menczer, J; Safra, T; Shpigel, S	1
Ayhan, A; Guler, N; Gultekin, M; Taskiran, C; Tuncer, S; Yigit-Celik, N; Yuce, K	1
Armstrong, DK; Bookman, MA; Bristow, RE; McGuire, W; Schilder, JM	1
Corrado, G; Samaritani, R; Sbiroli, C; Vizza, E	1
Alvero, AB; Brown, D; Matthews, M; Montagna, M; Mor, G	1
Camara, O; Fedders, M; Hartmann, M; Kath, R; Oelschläger, H; Schneider, A	1
Brown, S; Carey, MS; Dancey, JE; Hirte, HW; Hotte, SJ; Oza, AM; Pond, GR; Tsao, MS; Welch, S	1
Coleman, RL; Gaikwad, A; Saucier, JM; Smith, JA; Wolf, JK; Yu, J	1
Abushahin, F; Grendys, EC; Lurain, JR; Rademaker, AW; Schink, JC; Singh, DK	1
Belau, A; Bogenrieder, T; Camara, O; Coumbos, A; Klare, P; Koensgen, D; Lichtenegger, W; Mustea, A; Oskay-Oezcelik, G; Sehouli, J; Sommer, H; Steck, T; Stengel, D	1
Lehoczky, O; Pulay, T	1
Abu-Ghazaleh, SZ; Argenta, PA; Bliss, RL; Boente, MP; Carson, LF; Chen, MD; Downs, LS; Geller, MA; Ghebre, R; Judson, PL; Nahhas, WA	1
Chen, TT; Escalon, J; Hills, D; Hochster, H; Ivy, P; Liebes, L; Lu, JM; Muggia, F; Sorich, J	1
Cui, BX; Jiang, J; Kong, BH; Meng, LH; Su, SL; Wang, B; Wang, LJ; Yang, XS; Zhang, YZ	1
Bachvarov, D; Bachvarova, M; L'Espérance, S; Mes-Masson, AM; Tetu, B	1
Alvarez, RD; Andrews, S; Bryant, C; Heilbrun, LK; Malone, J; Morris, R; Munkarah, A; Schimp, V; Smith, D	1
Chamorey, E; Creisson, A; Ferrero, JM; Hebert, C; Largillier, R; Lesbats, G; Mari, V; Novo, C; Valenza, B	1
Chen, XY; Lihua, P; Wu, TX	1
Herzog, TJ; Wethington, SL; Wright, JD	1
Corti, C; Giardini, R; Pratesi, G; Tortoreto, M; Zunino, F	1
Chantarawiroj, P; Edwards, CL; Freedman, RS; Gonzalez de Leon, C; Hord, M; Kavanagh, JJ; Kim, EE; Kudelka, AP; Levenback, C; Madden, T; Raber, M; Tresukosol, D; Verschraegen, C; Wallin, B	1
Beijnen, JH; Creemers, GJ; Davies, B; de Boer-Dennert, M; McDonald, M; Rosing, H; Schellens, JH; Verweij, J	1
Fields, AL; Goldberg, GL; Runowicz, CD	1
Beijnen, JH; Creemers, GJ; Davies, BE; de Boer-Dennert, M; Maes, RA; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ; Verweij, J	1
Barnett, AA	1
Catimel, G; Talon, A	1
Bolis, G; Creemers, GJ; Despax, R; Favalli, G; Gore, M; Guastalla, JP; Hudson, I; Kreinberg, R; Lacave, AJ; Scarfone, G; Ten Bokkel Huinink, WW; Van Belle, S; Verweij, J	1
Broom, C	1
Alvarez, RD; Armstrong, DK; Barker, SD; Bookman, MA; Fleming, GF; Horowitz, IR; McGuire, WP; O'Reilly, S; Ozols, RF; Rowinsky, EK; Schilder, RJ; Walczak, JR	1
Armstrong, D; Carmichael, J; Gordon, A; Malfetano, J; ten Bokkel Huinink, W	1
Dunton, CJ	1
Janik, JE; Saltz, L	1
Heuser, A; Sauer, R	1
Ozols, RF	2
Bolis, G; Broom, C; Carmichael, J; Coleman, R; Davidson, N; Fields, SC; Gordon, A; Gore, M; Heron, JF; Hudson, I; Malfetano, J; Malmström, H; Scarabelli, C; Spanczynski, M; ten Bokkel Huinink, W	1
Bolis, G; Despax, R; Gore, M; Gwyther, S; Hudson, IR; Jiménez-Lacave, A; ten Bokkel Huinink, W; Verweij, J	1
Elbendary, A; Herzog, TJ; Mutch, DG; Rader, JS; Swisher, EM	1
Paterson, DL	1
Coleman, RL; Miller, DS	1
Armstrong, DK; Grochow, LB; O'Reilly, S	1
Astoul, C; Ollitrault, N; Salvat, D	1
Bulusu, VR	1
Carenini, N; Perego, P; Pratesi, G; Romanelli, S; Tortoreto, M; Zunino, F	1
Adler, H; Buckley, M; Cho, J; Dar, K; Fry, D; Hochster, H; Kim, T; Liebes, L; Pease, D; Potmesil, M; Zeleniuch-Jacquotte, A	1
Cass, I; Fields, AL; Goldberg, GL; Kuo, DY; Runowicz, CD	1
Abendstein, B; Klingler, PJ; Sevin, BU	1
Beare, S; Bryson, P; Capstick, V; Drouin, P; Eisenhauer, E; Grimshaw, R; Hoskins, P; Roy, M; Stuart, G; Zee, B	1
Kolker, HJ; Loos, WJ; Ma, J; Maliepaard, M; Nooter, K; Schellens, JH; Stoter, G; Verweij, J	1
Carlson, JA; Dunton, CJ; Neufeld, J	1
Brown, R; McDonald, AC	1
Beijnen, JH; Bult, A; Doyle, E; Rosing, H; van Zomeren, DM	1
Bolis, G; Bookman, MA; Fields, SZ; Gordon, A; Krebs, JB; Lissoni, A; Malmström, H	1
Brogden, RN; Wiseman, LR	1
Bedogné, B; Carenini, N; Caserini, C; Perego, P; Pratesi, G; Righetti, SC; Supino, R; Tortoreto, M; Zunino, F	1
Burris, H; Fields, S; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; van Beurden, V; van den Burg, ME; Verweij, J; von Hoff, DD	1
Cannistra, SA	1
Beijnen, JH; Beusenberg, FD; Doyle, E; Hearn, S; Herben, VM; Panday, VR; Richel, DJ; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van der Vange, N	1
Bozec, L; Goldwasser, F; Misset, JL; Zeghari-Squalli, N	1
Bleuzen, P; Buthaud, X; Cvitkovic, E; Goldwasser, F; Gross, M; Jasmin, C; Misset, JL; Romain, D; Voinea, A	1
Apicella, A; Cartení, G; Comella, G; Comella, P; Frasci, G; Gravina, A; Guida, T; Lapenta, L; Lombardi, R; Natale, M; Nicolella, GP; Pacilio, C; Panza, N	1
Chen, AY; Choy, H; Rothenberg, ML	1
Cohen, H; Hochster, H; Liebes, L; Runowicz, C; Sorich, J; Speyer, J; Taubes, B; Wadler, S; Wallach, R	1
Ghamande, SA; Piver, MS	1
Cesano, A; Fields, SZ; Lane, SR; Poulin, R; Ross, G	1
Cianci, C; Conte, PF; Gadducci, A	1
Blessing, JA; DeGeest, K; Herzog, TJ; Look, KY; Markman, M; Morgan, M; Rose, PG	1
Blessing, JA; Bookman, MA; Dunton, CJ; Lentz, SS; McGuire, WP	1
Lu, H; Nair, RV; Seiden, MV; Supko, JG	1
Cacciari, N; Martoni, A; Zamagni, C	1
Alvarez, RD; Blessing, JA; Hall, K; Hanjani, P; Markman, M; Waggoner, S	1
Engelholm, SA; Nielsen, D; Nielsen, HA	1
Fleming, GF; Janisch, L; Ratain, MJ; Ryan, CW	1
Ferguson, MJ; Rankin, EM	1
Aguilar-Cordova, E; Hasenburg, A; Kaplan, A; Kaufman, RH; Kieback, CC; Kieback, DG; Nyberg-Hoffman, C; Ramzy, I; Rojas-Martinez, A; Tong, XW	1
Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW	1
Fluellen, L; Fusco, N; Gordon, NH; Hoppel, CL; Ingalls, ST; Rodriguez, M; Rose, PG	1
Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K	1
Brown, JV; Dillman, RA; Drescher, CW; Karlan, BY; Micha, JP; Peters, WA; Rettenmaier, MA; Smith, MR	1
Dubuc-Lissoir, J; Eisenhauer, E; Fisher, B; Grimshaw, R; Hoskins, P; Oza, A; Plante, M; Stuart, G; Vergote, I; Vermorken, J	1
Lambrou, N; Trimble, EL	1
D'Agostino, G; Ferrandina, G; Greggi, S; Lorusso, D; Mancuso, S; Manzione, L; Salerno, MG; Scambia, G	1
Beijnen, JH; Jonker, JW; Maliepaard, M; Scheffer, GL; Schellens, JH; Scheper, RJ; Schinkel, AH; Smit, JW	1
Bevers, M; Kavanagh, JJ; Kudelka, AP; Levenback, C; Loyer, E; Verschraegen, CF; Vincent, M; Wolf, J	1
Broggini, M; Galliera, E; Marabese, M; Marchini, S; Vikhanskaya, F	1
Figueroa, JA; Herrington, JD; Kirstein, MN; Stewart, CF; Zamboni, WC	1
Fanucchi, MP; Giblin, J; McGuire, WP	1
Bolis, G; Carmichael, J; Coleman, R; Davidson, N; Fields, SZ; Gordon, A; Gore, M; Héron, JF; Malfetano, J; Malmström, H; Ross, G; Scarabelli, C; Spaczynski, M; ten Bokkel Huinink, W; Vennin, P	1
Malik, IA	1
Beckman, RA; Gore, M; Hearn, S; Lane, SR; Ross, G; Rustin, G; Schüller, J	1
Allen, D; Davison, J; Gates, P; Neesham, D; Planner, R; Prince, HM; Quinn, M; Rischin, D	1
Bolis, G; Parazzini, F; Scarfone, G; Villa, A	1
Avula, R; Bible, KC; Hartmann, LC; Huang, H; Kalli, K; Kaufmann, SH; Lee, YK; Shridhar, V; Smith, DI; Staub, J	1
Shen, J; Sun, Z	1
Shen, K; Sun, Z; Xu, X	1
Learned, J	1
Bowman, A; Ross, G; Rye, T; Smyth, JF; Wheatley, A	1
Gerçel-Taylor, C; Manahan, KJ; Taylor, DD	1
Fleagle, JT; Gordon, AN; Gore, ME; Guthrie, D; Lacave, AJ; Parkin, DE	1
Aleman, AS; Bast, RC; Bevers, MW; Bodurka-Bevers, D; Burke, TW; Champlin, RE; Donato, ML; Freedman, RS; Gajewski, JL; Gershenson, DM; Ippoliti, CM; Levenback, CF; Wharton, JT; Wolf, JK	1
Berkowitz, RS; Campos, SM; Cook, S; Fuller, AF; Goodman, A; MacNeill, KM; Matulonis, UA; Penson, RT; Seiden, MV; Supko, JG	1
Beckman, RA; Clarke-Pearson, DL; DeWitte, MH; Fields, SZ; Hanjani, P; Iveson, T; Kristensen, G; Lane, SR; Malfetano, JH; Ross, GA; Van Le, L; Whitney, CW	1
Bugat, R; Canal, P; Chatelut, E; Guichard, S; Hennebelle, I; Montazeri, A	1
Rodriguez, M; Rose, PG	1
Hall, DJ; Homesley, HD; Lewandowski, GS; Martin, DA; Nahhas, WA; Penley, RG; Suggs, CL; Vaccarello, L	1
De Vincenzo, R; Distefano, M; Ferlini, C; Gaggini, C; Mancuso, S; Scambia, G	1
Bagnall, AM; Duffy, S; Forbes, C; Shirran, L; ter Riet, G	1
Camlett, I; de Jonge, MJ; Gelderblom, H; Hennis, B; Loos, WJ; Mantel, MA; Sparreboom, A; van der Burg, ME; Verweij, J; Wilms, E	1
Astre, C; Boucaud, M; Bressolle, F; Culine, S; Cupissol, D; Pinguet, F; Poujol, S; Romieu, G	1
Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Souglakos, J; Vamvakas, L; Vardakis, N	1
Bolis, G; Guarnerio, P; Parazzini, F; Polverino, GP; Rosa, C; Scarfone, G; Sciatta, C	1
Aguilar-Cordova, E; Fischer, DC; Hasenburg, A; Kaplan, AL; Kaufman, RH; Kieback, DG; Nyberg-Hoffman, C; Ramzy, I; Rojas-Martinez, A; Tong, XW	1
du Bois, A	1
Aalders, JG; Beijnen, JH; Bos, AM; de Vries, EG; Hofstra, LS; Mulder, NH; Rosing, H; van der Zee, AG; Willemse, PH	1
de Jonge, MJ; Sparreboom, A; Verweij, J	1
Beckman, RA; Calvert, H; Carmichael, J; Clarke-Pearson, D; Fields, SZ; Gore, M; Malfetano, J; Oza, A; Ross, G; Rustin, G	1
Feng, F; He, X; Shi, Y	1
Albin, N; Bugat, R; Canal, P; Chatelut, E; Culine, S; Déporte-Féty, R; Goupil, A; Laguerre, B; Lokiec, F; Montazeri, A; Pinguet, F	1
Thigpen, T	1
Li, H; Liu, L; Zhang, W	1
Clark, JW; Eder, JP; Huang, KC; Kwiatkowski, D; Lynch, T; Ng, SW; Ryan, DP; Seiden, MV; Skarin, A; Supko, JG	1
Beijnen, JH; de Jong, LA; Herben, VM; Pluim, D; Schellens, JH; Schoemaker, NE; ten Bokkel Huinink, WW; van Waardenburg, RC	1
Doherty, MG; Gordon, AN; Hancock, KC; Matthews, CM; Messing, M; Stringer, CA; Teneriello, M	1
Aguilar-Cordova, E; Engehausen, DG; Fischer, DC; Kieback, DG; Oehler, MK; Sauerbrei, W; Tong, XW	1
Hanjani, P; Nolte, S; Shahin, MS	1
Bianco, AR; Catalano, G; Ciardiello, F; Damiano, V; De Laurentiis, M; De Placido, S; Matano, E; Pensabene, M; Pepe, S; Tortora, G	1
Malmström, H; Peterson, C; Zackrisson, AL	1
Crane, MM; Hunter, JE; Puls, LE	1
Bagaméri, A; Lehoczky, G; Lehoczky, O; Pulay, T	1
Hensley, ML	1
Chen, BM; Chern, JW; Leu, YL; Prijovich, ZM; Roffler, SR	1
Ettinger, DS; Forastiere, AA; Grochow, LB; Hendricks, CB; Hurowitz, LA; Kaufmann, SH; Lubejko, BG; McGuire, WP; Rowinsky, EK; Sartorius, SE	1

Reviews

53 review(s) available for topotecan and Ovarian Neoplasms

Article	Year
Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2019, Volume: 29, Issue:9 Topics: Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Randomized Controlled Trials as Topic; Topotecan	2019
Targeting DNA repair and replication stress in the treatment of ovarian cancer. International journal of clinical oncology, 2017, Volume: 22, Issue:4 Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Cell Cycle; Cisplatin; DNA Damage; DNA Repair; DNA Replication; DNA-Binding Proteins; Female; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Topotecan	2017
Refractory Small Cell Carcinoma of the Ovary - Hypercalcemic Type (SCCOHT) Treated with Romidepsin and Topotecan: A Case Report and Review of the Literature. Connecticut medicine, 2016, Volume: 80, Issue:9 Topics: Antibiotics, Antineoplastic; Carcinoma, Small Cell; Depsipeptides; Disease Progression; Fatal Outcome; Female; Humans; Ovarian Neoplasms; Ovariectomy; Topoisomerase I Inhibitors; Topotecan; Young Adult	2016
The prognostic and predictive role of pain before systemic chemotherapy in recurrent ovarian cancer: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Pain; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Predictive Value of Tests; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Topotecan	2020
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2015, Volume: 19, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom	2015
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids	2015
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer. Gynecologic oncology, 2016, Volume: 140, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult	2016
Current role and future aspects of topotecan in relapsed ovarian cancer. Current medical research and opinion, 2009, Volume: 25, Issue:3 Topics: Antineoplastic Agents; Female; Humans; Ovarian Neoplasms; Recurrence; Topotecan	2009
First-line chemotherapy in epithelial ovarian cancer. Clinical obstetrics and gynecology, 2012, Volume: 55, Issue:1 Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A	2012
Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials. Journal of chemotherapy (Florence, Italy), 2012, Volume: 24, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Topotecan	2012
Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule? The oncologist, 2002, Volume: 7, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Topotecan; Treatment Outcome	2002
Update on the role of topotecan in the treatment of recurrent ovarian cancer. The oncologist, 2002, Volume: 7 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Rate; Topotecan	2002
Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. The oncologist, 2002, Volume: 7 Suppl 5 Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2002
Emerging role of topotecan in front-line treatment of carcinoma of the ovary. The oncologist, 2002, Volume: 7 Suppl 5 Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Ovarian Neoplasms; Salvage Therapy; Topotecan	2002
[Gemicitabine in the treatment of epithelial ovarian cancer]. Bulletin du cancer, 2002, Volume: 89 Spec No Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prodrugs; Remission Induction; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine	2002
Current therapies in ovarian cancer. Cancer investigation, 2003, Volume: 21, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Drug Approval; Female; Forecasting; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Topotecan; Treatment Outcome; United States; United States Food and Drug Administration	2003
Clinical experience with topotecan in relapsed ovarian cancer. Gynecologic oncology, 2003, Volume: 90, Issue:3 Pt 2 Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Topotecan	2003
First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecologic oncology, 2003, Volume: 90, Issue:3 Pt 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids; Topotecan	2003
Weekly topotecan in the management of ovarian cancer. Gynecologic oncology, 2003, Volume: 90, Issue:3 Pt 2 Topics: Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Topotecan	2003
Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecologic oncology, 2003, Volume: 90, Issue:3 Pt 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Salvage Therapy; Topotecan	2003
Workshop: options for therapy in ovarian cancer. Gynecologic oncology, 2003, Volume: 90, Issue:3 Pt 2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan	2003
Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. The oncologist, 2004, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Incidence; Ovarian Neoplasms; Practice Guidelines as Topic; Receptors, Colony-Stimulating Factor; Recurrence; Risk Factors; Topotecan	2004
Treatment advances in ovarian cancer. Cancer nursing, 2003, Volume: 26, Issue:6 Suppl Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Humans; Ovarian Neoplasms; Salvage Therapy; Topotecan; Treatment Outcome	2003
Review of the use of topotecan in ovarian carcinoma. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:11 Topics: Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Ovarian Neoplasms; Topotecan	2004
Recurrent ovarian cancer: how important is it to treat to disease progression? Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22 Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan	2004
Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations. Cancer investigation, 2004, Volume: 22, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Female; Guidelines as Topic; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Topotecan	2004
Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. The oncologist, 2005, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Bone Marrow; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Topotecan	2005
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2006, Volume: 10, Issue:9 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cost-Benefit Analysis; Doxorubicin; Female; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan	2006
Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:8 Topics: Antineoplastic Agents; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Topotecan	2006
Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management. Danish medical bulletin, 2006, Volume: 53, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Denmark; Diagnostic Imaging; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Outcome	2006
Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. Expert opinion on drug safety, 2007, Volume: 6, Issue:1 Topics: Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2007
Topotecan for ovarian cancer. The Cochrane database of systematic reviews, 2008, 04-16, Issue:2 Topics: Antineoplastic Agents; Doxorubicin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Topotecan	2008
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert review of anticancer therapy, 2008, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	2008
Promising new therapies in the treatment of advanced ovarian cancer. Cancer, 1995, Nov-15, Volume: 76, Issue:10 Suppl Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topotecan	1995
Clinical studies of topotecan. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Topotecan	1996
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Remission Induction; Safety; Survival Rate; Topoisomerase I Inhibitors; Topotecan	1997
New options for the treatment of advanced ovarian cancer. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Remission Induction; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	1997
Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor? Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
[Topoisomerase I inhibitor with potential radiosensitizing effect]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1997, Volume: 173, Issue:3 Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Child; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topoisomerase I Inhibitors; Topotecan	1997
Future directions in the chemotherapy of ovarian cancer. Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15 Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine	1997
Topotecan in the treatment of gynecologic cancer. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 20 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Genital Neoplasms, Female; Humans; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Uterine Cervical Neoplasms	1997
Topotecan. A review of its potential in advanced ovarian cancer. Drugs, 1998, Volume: 56, Issue:4 Topics: Antineoplastic Agents; Female; Humans; Ovarian Neoplasms; Topotecan	1998
Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The oncologist, 1999, Volume: 4, Issue:2 Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Recurrence; Salvage Therapy; Time Factors; Topotecan	1999
DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:10 Suppl 5 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan	1999
Up date in the management of advanced ovarian carcinoma. Critical reviews in oncology/hematology, 1999, Volume: 32, Issue:1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Topotecan	1999
Dose-intensive approaches to ovarian cancer. Current oncology reports, 1999, Volume: 1, Issue:1 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Prognosis; Survival Analysis; Topotecan	1999
[DNA topoisomerase I inhibitor in the treatment of ovarian neoplasm]. Zhonghua fu chan ke za zhi, 1999, Volume: 34, Issue:6 Topics: Antineoplastic Agents; Female; Humans; Ovarian Neoplasms; Pregnancy; Topoisomerase I Inhibitors; Topotecan	1999
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2001, Volume: 11 Suppl 1 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; DNA Adducts; Female; Gemcitabine; Humans; Immunologic Factors; Liposomes; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topoisomerase I Inhibitors; Topotecan	2001
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Health technology assessment (Winchester, England), 2001, Volume: 5, Issue:28 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Technology Assessment, Biomedical; Topotecan	2001
Treatment of advanced ovarian cancer. European journal of cancer (Oxford, England : 1990), 2001, Volume: 37 Suppl 9 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan	2001
The role of gemcitabine-based doublets in the management of ovarian carcinoma. Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine	2002
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan	2002
Epithelial ovarian cancer. Current treatment options in oncology, 2002, Volume: 3, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine	2002

Trials

164 trial(s) available for topotecan and Ovarian Neoplasms

Article	Year
Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. Journal of gynecologic oncology, 2022, Volume: 33, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan	2022
Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ). Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Leukopenia; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Topotecan	2023
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2019, Volume: 29, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Progression-Free Survival; Receptor, ErbB-3; RNA, Messenger; Topotecan	2019
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome	2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-10, Volume: 38, Issue:32 Topics: Adult; Aged; Benzimidazoles; Cystadenocarcinoma, Serous; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Protein Kinase Inhibitors; Topotecan; Young Adult	2020
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jun-01, Volume: 28, Issue:6 Topics: Aged; Antineoplastic Agents; Carbolines; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Ovarian Neoplasms; Platinum; Topotecan	2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Oct-10, Volume: 35, Issue:29 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome	2017
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology, 2018, Volume: 19, Issue:9 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Germany; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Sorafenib; Time Factors; Topoisomerase I Inhibitors; Topotecan	2018
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. Cancer treatment and research communications, 2018, Volume: 14 Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan	2018
Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study. Minerva ginecologica, 2019, Volume: 71, Issue:3 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Topotecan	2019
Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. European journal of cancer (Oxford, England : 1990), 2019, Volume: 117 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nomograms; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Topotecan	2019
Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:3 Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Israel; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Topotecan	2013
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Infusion Pumps; Middle Aged; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Survival Analysis; Topotecan	2013
Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness. The oncologist, 2014, Volume: 19, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Collagen; Epitopes; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Neoplasm Invasiveness; Ovarian Neoplasms; Quinazolines; Topotecan	2014
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, May-01, Volume: 32, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topotecan	2014
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, May-01, Volume: 32, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Self Report; Topotecan; Treatment Outcome	2014
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult	2014
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecologic oncology, 2014, Volume: 135, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Recombinant Fusion Proteins; Topoisomerase I Inhibitors; Topotecan	2014
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-10, Volume: 33, Issue:32 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polyethylene Glycols; Prognosis; Risk Factors; Topotecan; Treatment Outcome	2015
Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. British journal of cancer, 2015, Sep-01, Volume: 113, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Pancreatic Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome; Young Adult	2015
Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Image; Carboplatin; Cisplatin; Disease-Free Survival; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Quality of Life; Surveys and Questionnaires; Topotecan	2016
A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study. Chemotherapy, 2016, Volume: 61, Issue:1 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Salvage Therapy; Survival Rate; Topotecan; Young Adult	2016
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer. Gynecologic oncology, 2016, Volume: 142, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topotecan	2016
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan	2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life; Topotecan	2016
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecologic oncology, 2017, Volume: 144, Issue:1 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Hypertension; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Selection; Platinum Compounds; Polyethylene Glycols; Topotecan	2017
Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma. Cancer, 2008, Aug-01, Volume: 113, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Female; Humans; Infusions, Parenteral; Middle Aged; Models, Biological; Ovarian Neoplasms; Peritoneal Neoplasms; Salvage Therapy; Survival Analysis; Topotecan; Treatment Outcome	2008
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium. Gynecologic oncology, 2008, Volume: 110, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quality of Life; Topotecan	2008
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-01, Volume: 26, Issue:19 Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Deoxycytidine; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Proportional Hazards Models; Quality of Life; Survival Rate; Topotecan; Treatment Outcome	2008
Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecologic oncology, 2008, Volume: 111, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan; Vinblastine; Vinorelbine	2008
A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer. American journal of clinical oncology, 2008, Volume: 31, Issue:5 Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Prognosis; Survival Rate; Topotecan	2008
Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:6 Topics: Alopecia; Anemia; Antineoplastic Agents; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Multivariate Analysis; Nausea; Neutropenia; Ovarian Neoplasms; Salvage Therapy; Survival Analysis; Topotecan; Treatment Outcome; Vomiting	2009
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-20, Volume: 27, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Topotecan	2009
A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecologic oncology, 2009, Volume: 113, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Survival Analysis; Taxoids; Topotecan; Uterine Neoplasms	2009
Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO). Thrombosis research, 2009, Volume: 124, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Venous Thromboembolism	2009
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekolog Gynecologic oncology, 2009, Volume: 114, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Rate; Topotecan	2009
Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study. Gynecologic oncology, 2009, Volume: 114, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Epithelial Cells; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate; Topotecan	2009
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Doxorubicin; Drug Resistance, Neoplasm; Female; Glutathione; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Topotecan; Treatment Outcome	2009
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone marrow transplantation, 2010, Volume: 45, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2010
Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study. Gynecologic oncology, 2009, Volume: 115, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Quality of Life; Topotecan; Treatment Outcome	2009
Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:16 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Outcome; Young Adult	2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. Journal of the National Cancer Institute, 2010, Oct-20, Volume: 102, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Staging; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure	2010
A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:3 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Cohort Studies; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Salvage Therapy; Survival Rate; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan	2011
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer. Gynecologic oncology, 2011, Volume: 120, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2011
Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Cohort Studies; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Lactones; Middle Aged; Neutropenia; Ovarian Neoplasms; Remission Induction; Stomach Neoplasms; Survival Analysis; Topoisomerase I Inhibitors; Topotecan	2011
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-10, Volume: 29, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Quality of Life; Topoisomerase I Inhibitors; Topotecan	2011
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecologic oncology, 2011, Volume: 120, Issue:3 Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Topoisomerase I Inhibitors; Topotecan	2011
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecologic oncology, 2011, Volume: 122, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Receptor, ErbB-2; Survival Rate; Topotecan	2011
A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma. International journal of clinical oncology, 2011, Volume: 16, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Thalidomide; Topotecan	2011
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan	2012
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer, 2011, Aug-15, Volume: 117, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Topotecan	2011
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecologic oncology, 2011, Volume: 123, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Topotecan	2011
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecologic oncology, 2012, Volume: 124, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Polymorphism, Genetic; Topotecan; Young Adult	2012
Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study. Anti-cancer drugs, 2012, Volume: 23, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anemia; Cohort Studies; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Uterine Neoplasms	2012
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult	2012
Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Synergism; Female; Fever; Humans; Infections; Male; Middle Aged; Neoplasms; Nervous System Diseases; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Patient Dropouts; Thrombocytopenia; Topotecan; Treatment Outcome	2002
A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:11 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Probability; Survival Analysis; Topotecan; Treatment Failure; Treatment Outcome	2002
[Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer]. Ai zheng = Aizheng = Chinese journal of cancer, 2002, Volume: 21, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Recurrence; Topotecan; Treatment Outcome	2002
A phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients. Gynecologic oncology, 2002, Volume: 87, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Dose-Response Relationship, Drug; Drug Administration Schedule; Epithelial Cells; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan	2002
Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecologic oncology, 2003, Volume: 88, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Epithelial Cells; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Recombinant Proteins; Topotecan	2003
[Own experiences in salvage chemotherapy of ovarian cancer--a preliminary report]. Ginekologia polska, 2002, Volume: 73, Issue:11 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Time Factors; Topotecan; Treatment Outcome	2002
Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecologic oncology, 2003, Volume: 90, Issue:2 Pt 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Liposomes; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan	2003
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. Cancer, 2003, Oct-15, Volume: 98, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2003
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Topotecan	2004
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecologic oncology, 2003, Volume: 91, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2003
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Administration Schedule; Female; Humans; Incidence; Infusions, Intravenous; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Topotecan	2004
[Economic assessment of Caelyx versus topotecan in advanced ovarian cancer]. Bulletin du cancer, 2003, Volume: 90, Issue:11 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Doxorubicin; Drug Costs; Female; Hospital Costs; Humans; Ovarian Neoplasms; Quality of Life; Topotecan	2003
Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? British journal of cancer, 2004, Jan-26, Volume: 90, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carcinoma; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Reference Values; Topotecan; Treatment Outcome; World Health Organization	2004
A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. British journal of cancer, 2004, Feb-23, Volume: 90, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Analysis; Topotecan; Treatment Outcome	2004
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum. Onkologie, 2004, Volume: 27, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure	2004
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecologic oncology, 2004, Volume: 93, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Carriers; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Middle Aged; Ovarian Neoplasms; Topotecan	2004
Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecologic oncology, 2004, Volume: 93, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Salvage Therapy; Topotecan	2004
Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan	2004
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-01, Volume: 22, Issue:13 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome	2004
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. Gynecologic oncology, 2004, Volume: 94, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan	2004
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecologic oncology, 2004, Volume: 95, Issue:1 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Survival Rate; Topotecan	2004
Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic oncology, 2004, Volume: 95, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Topotecan	2004
Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 1 Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Chromatography, High Pressure Liquid; Disease Progression; DNA; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Recurrence; Time Factors; Topotecan; Treatment Outcome	2004
Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecologic oncology, 2004, Volume: 95, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Epithelial Cells; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2004
Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study. Cancer, 2005, Apr-01, Volume: 103, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Administration Schedule; Etoposide; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Taxoids; Topotecan	2005
A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Outcome	2005
Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. British journal of cancer, 2005, Jul-11, Volume: 93, Issue:1 Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Middle Aged; Organophosphorus Compounds; Ovarian Neoplasms; Quality of Life; Recurrence; Topotecan	2005
A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecologic oncology, 2005, Volume: 99, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2005
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Liposomes; Male; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Polyethylene Glycols; Topotecan; Treatment Outcome; Vomiting	2005
A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study. Gynecologic oncology, 2006, Volume: 100, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2006
Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study. Gynecologic oncology, 2006, Volume: 100, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Topotecan	2006
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Salivary Gland Neoplasms; Staurosporine; Survival Analysis; Topotecan	2006
Phase I clinical trial of topotecan and pegylated liposomal doxorubicin. Cancer investigation, 2005, Volume: 23, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Ovarian Neoplasms; Polyethylene Glycols; Topotecan	2005
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC cancer, 2006, Jan-07, Volume: 6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Severity of Illness Index; Time Factors; Topotecan	2006
Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study. Gynecologic oncology, 2006, Volume: 102, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2006
Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol. Bone marrow transplantation, 2006, Volume: 37, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Survival Rate; Topotecan; Treatment Outcome	2006
Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecologic oncology, 2006, Volume: 103, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Drug Administration Schedule; Epithelial Cells; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Topotecan	2006
Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecologic oncology, 2006, Volume: 103, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Epithelial Cells; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2006
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecologic oncology, 2006, Volume: 103, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan	2006
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute, 2006, Aug-02, Volume: 98, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Female; France; Germany; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Topotecan; Treatment Failure	2006
A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma. Gynecologic oncology, 2007, Volume: 104, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Topotecan	2007
A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecologic oncology, 2007, Volume: 104, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelial Cells; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Topotecan	2007
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Remission Induction; Thrombocytopenia; Topotecan; Treatment Outcome	2007
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. The oncologist, 2007, Volume: 12, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CA-125 Antigen; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Retrospective Studies; Topotecan; Treatment Outcome	2007
Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecologic oncology, 2007, Volume: 105, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Topotecan	2007
A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Gynecologic oncology, 2007, Volume: 105, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Topotecan	2007
UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecologic oncology, 2007, Volume: 106, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Staurosporine; Topotecan	2007
Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prospective Studies; Topotecan	2008
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer, 2008, Jan-15, Volume: 112, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Thalidomide; Topotecan	2008
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecologic oncology, 2008, Volume: 108, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Topotecan; Treatment Outcome	2008
[Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer]. Zhonghua fu chan ke za zhi, 2007, Volume: 42, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Topotecan; Treatment Outcome	2007
Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecologic oncology, 2008, Volume: 109, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Survival Rate; Topotecan	2008
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan	1996
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. British journal of cancer, 1996, Volume: 73, Issue:10 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Carcinoma, Small Cell; Colonic Neoplasms; Cross-Over Studies; Female; Humans; Hydroxy Acids; Lactones; Male; Metabolic Clearance Rate; Middle Aged; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1996
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:3 Topics: Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Ovarian Neoplasms; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan	1996
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelium; Female; Humans; Middle Aged; Ovarian Neoplasms; Topotecan	1996
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Vomiting	1997
[Topotecan--a new principle of effectiveness in oncology. 4th Salzburg Symposium on Quality of Life. 15-17 December 1995]. Geburtshilfe und Frauenheilkunde, 1996, Volume: 56, Issue:6 Suppl Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Topotecan	1996
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan	1997
Experience with independent radiological review during a topotecan trial in ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Middle Aged; Ovarian Neoplasms; Tomography, X-Ray Computed; Topotecan	1997
Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecologic oncology, 1997, Volume: 66, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Analysis; Topotecan; Treatment Outcome	1997
Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:3 Topics: Adenoma, Islet Cell; Antineoplastic Agents; Autoantibodies; Autoantigens; Biomarkers; Biopsy; Breast Neoplasms; Cell Line; DNA Topoisomerases, Type I; Endometrial Neoplasms; Esophageal Neoplasms; Female; Gastrointestinal Neoplasms; HeLa Cells; Humans; Lung Neoplasms; Nuclear Proteins; Ovarian Neoplasms; Pancreatic Neoplasms; Scleroderma, Systemic; Stomach Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1998
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:6 Topics: Adolescent; Adult; Aged; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Ovarian Neoplasms; Topotecan; Treatment Outcome	1998
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome	1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:7 Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Fatigue; Female; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Topotecan; Treatment Outcome	1998
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan	1999
Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anti-cancer drugs, 1999, Volume: 10, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platelet Count; Prospective Studies; Thrombocytopenia; Topotecan	1999
Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Topotecan; Treatment Outcome	1999
Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cisplatin; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Topotecan; Treatment Outcome	1999
Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study. Journal of surgical oncology, 1999, Volume: 72, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Salvage Therapy; Topotecan	1999
Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial. Gynecologic oncology, 1999, Volume: 75, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Topotecan	1999
Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Salvage Therapy; Topotecan; Treatment Outcome	2000
The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support? European journal of gynaecological oncology, 2000, Volume: 21, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan	2000
Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. Gynecologic oncology, 2000, Volume: 77, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Palliative Care; Thrombocytopenia; Topotecan; Treatment Outcome	2000
Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer. Gynecologic oncology, 2000, Volume: 77, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Carcinoma; Female; Humans; Middle Aged; Ovarian Neoplasms; Topotecan; Treatment Outcome	2000
A phase I study of liposomal doxorubicin (Doxil) with topotecan. American journal of clinical oncology, 2000, Volume: 23, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan	2000
Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer gene therapy, 2000, Volume: 7, Issue:6 Topics: Acyclovir; Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenoviridae; Adult; Aged; Antiviral Agents; Combined Modality Therapy; Cystadenocarcinoma, Papillary; DNA; Enzyme Inhibitors; Female; Follow-Up Studies; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polymerase Chain Reaction; Thymidine Kinase; Topotecan	2000
A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecologic oncology, 2000, Volume: 78, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Lactones; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan	2000
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecologic oncology, 2000, Volume: 79, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan	2000
A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecologic oncology, 2000, Volume: 79, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Epithelium; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Klebsiella Infections; Klebsiella pneumoniae; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Sleep Stages; Topotecan	2000
Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-15, Volume: 18, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epithelium; Feasibility Studies; Female; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Survival Rate; Topotecan; Vomiting	2000
Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology, 2001, Volume: 60, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Topotecan; Treatment Outcome	2001
Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Topotecan	2000
Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-01, Volume: 19, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cross-Over Studies; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Europe; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate; Topotecan; United States	2001
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. British journal of cancer, 2001, Apr-20, Volume: 84, Issue:8 Topics: Abdominal Pain; Adult; Aged; Alopecia; Antineoplastic Agents; Diarrhea; Fatigue; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Nausea; Ovarian Neoplasms; Survival Analysis; Survival Rate; Time Factors; Topotecan; Treatment Outcome; Vomiting	2001
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. Gynecologic oncology, 2001, Volume: 81, Issue:2 Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan	2001
Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer. Gynecologic oncology, 2001, Volume: 81, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan	2001
Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jul-01, Volume: 19, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Survival Rate; Topotecan	2001
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jul-15, Volume: 19, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Doxorubicin; Female; Humans; Liposomes; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Sickness Impact Profile; Survival Analysis; Topotecan	2001
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecologic oncology, 2001, Volume: 82, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate; Topotecan	2001
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer, 2001, Sep-01, Volume: 92, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Statistics, Nonparametric; Survival Rate; Topotecan	2001
Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-01, Volume: 19, Issue:19 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Survival Rate; Topotecan	2001
A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecologic oncology, 2001, Volume: 83, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Middle Aged; Ovarian Neoplasms; Topotecan	2001
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer. British journal of cancer, 2001, Oct-19, Volume: 85, Issue:8 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Glycerol; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2001
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors. Oncology, 2001, Volume: 61, Issue:4 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms	2001
A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecologic oncology, 2001, Volume: 83, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Topotecan	2001
Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecologic oncology, 2001, Volume: 83, Issue:3 Topics: Acyclovir; Adenoviridae; Adult; Aged; Antineoplastic Agents; Antiviral Agents; Combined Modality Therapy; Enzyme Inhibitors; Female; Genetic Therapy; Humans; Middle Aged; Ovarian Neoplasms; Second-Look Surgery; Thymidine Kinase; Topotecan	2001
A phase I and pharmacokinetic study of intraperitoneal topotecan. British journal of cancer, 2001, Nov-30, Volume: 85, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Exanthema; Fatigue; Female; Humans; Injections, Intraperitoneal; Metabolic Clearance Rate; Middle Aged; Nausea; Ovarian Neoplasms; Topotecan; Treatment Outcome; Vomiting	2001
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Tomography, X-Ray Computed; Topotecan	2002
[Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2001, Volume: 23, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Leukopoiesis; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan; Treatment Outcome	2001
Individual adaptive dosing of topotecan in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:2 Topics: Aged; Antineoplastic Agents; Area Under Curve; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neutrophils; Ovarian Neoplasms; Time Factors; Topotecan; Treatment Outcome	2002
A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:3 Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; DNA Primers; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Safety; Topotecan; Treatment Outcome	2002
Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer. Gynecologic oncology, 2002, Volume: 85, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan	2002
Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer. Gynecologic oncology, 2002, Volume: 85, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2002
Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:3 Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Topotecan; Tumor Cells, Cultured	2002
No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. European journal of clinical pharmacology, 2002, Volume: 58, Issue:2 Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Drug Interactions; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Topotecan	2002
Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma. Medical oncology (Northwood, London, England), 2002, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Time Factors; Topotecan; Treatment Outcome	2002
[Early results of topotecan therapy in patients with recurrent ovarian cancer]. Orvosi hetilap, 2002, Apr-21, Volume: 143, Issue:16 Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2002
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Topotecan	1992

Other Studies

188 other study(ies) available for topotecan and Ovarian Neoplasms

Article	Year
Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin. Journal of medicinal chemistry, 1996, Feb-02, Volume: 39, Issue:3 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Ovarian Neoplasms; Solubility; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Water	1996
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer research, 1999, Sep-15, Volume: 59, Issue:18 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Resistance, Multiple; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kinetics; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured	1999
Camptothecins in tumor homing via an RGD sequence mimetic. Bioorganic & medicinal chemistry letters, 2012, Oct-15, Volume: 22, Issue:20 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Integrins; Male; Oligopeptides; Ovarian Neoplasms; Prostatic Neoplasms; Rats	2012
The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Doxorubicin and Topotecan Resistant Ovarian Cancer Cell Lines. International journal of molecular sciences, 2022, May-23, Volume: 23, Issue:10 Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Doxorubicin; Female; Humans; MicroRNAs; Ovarian Neoplasms; Topotecan	2022
FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment. Molecular cancer therapeutics, 2023, Dec-01, Volume: 22, Issue:12 Topics: Ammonia; Animals; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Macrophages; Mice; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Microenvironment	2023
The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines. Advances in medical sciences, 2023, Volume: 68, Issue:2 Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; RNA, Messenger; Topotecan; Transforming Growth Factor beta	2023
Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy. Medicine, 2020, Volume: 99, Issue:17 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy; Female; Humans; Middle Aged; Ovarian Neoplasms; Palliative Care; Recurrence; Retrospective Studies; Topotecan; Treatment Outcome	2020
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020, Volume: 30, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan	2020
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. British journal of cancer, 2021, Volume: 124, Issue:3 Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; DNA Damage; DNA Replication; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Female; G1 Phase Cell Cycle Checkpoints; Genes, BRCA2; Homologous Recombination; Humans; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred NOD; Mice, SCID; Naphthyridines; Neoplasm Grading; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; RNA Interference; RNA Polymerase I; Topoisomerase I Inhibitors; Topotecan	2021
New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines. Anticancer research, 2017, Volume: 37, Issue:4 Topics: ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Ovarian Neoplasms; Real-Time Polymerase Chain Reaction; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	2017
Bulletin du cancer, 2017, Volume: 104 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Topotecan	2017
New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines. Molecules (Basel, Switzerland), 2017, Oct-13, Volume: 22, Issue:10 Topics: Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; S100 Proteins; Topotecan	2017
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer. European journal of gynaecological oncology, 2017, Volume: 38, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan	2017
Treatment of platinum refractory or resistant ovarian cancer. The Lancet. Oncology, 2018, Volume: 19, Issue:9 Topics: Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Sorafenib; Topotecan	2018
The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines. International journal of molecular sciences, 2018, Sep-25, Volume: 19, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Calcium-Binding Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Matrix Gla Protein; Ovarian Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topotecan	2018
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041). Gynecologic oncology, 2019, Volume: 152, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Topotecan	2019
Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development. International journal of molecular sciences, 2018, Dec-23, Volume: 20, Issue:1 Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Cell Line, Tumor; Collagen Type I; Collagen Type III; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Humans; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Primary Cell Culture; Protein-Lysine 6-Oxidase; Retinal Dehydrogenase; Topotecan	2018
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years. Gynecologic oncology, 2019, Volume: 153, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Drug Administration Schedule; Epirubicin; Female; Humans; Medication Adherence; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Topotecan; Tumor Burden; Young Adult	2019
HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity. Molecular cancer research : MCR, 2019, Volume: 17, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2019
Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan. International journal of molecular sciences, 2019, Jun-05, Volume: 20, Issue:11 Topics: Area Under Curve; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Signal Transduction; Topotecan; Transcriptome; Up-Regulation	2019
Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base. Gynecologic oncology, 2019, Volume: 154, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Young Adult	2019
Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols. Acta pharmaceutica (Zagreb, Croatia), 2019, Mar-01, Volume: 69, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Topotecan; Treatment Outcome; Young Adult	2019
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer research, 2013, Jun-15, Volume: 73, Issue:12 Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Immunoblotting; Ovarian Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Sulfones; Topotecan	2013
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Topotecan	2013
Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Molecular cancer therapeutics, 2013, Volume: 12, Issue:6 Topics: Apoptosis; BRCA2 Protein; Cell Line, Tumor; DNA Fragmentation; Drug Synergism; Female; Histones; Humans; Indoles; Mutation; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topotecan; Ubiquitin-Protein Ligases	2013
Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin. Annals of surgical oncology, 2014, Volume: 21, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cystadenocarcinoma, Serous; Etoposide; Female; Floxuridine; Follow-Up Studies; Heterozygote; Humans; Injections, Intraperitoneal; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Survival Rate; Topotecan	2014
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. Angiogenesis, 2014, Volume: 17, Issue:3 Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Inhibitory Concentration 50; Irinotecan; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome	2014
Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. Gynecologic oncology, 2014, Volume: 133, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Taxoids; Topotecan	2014
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:5 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured	2014
Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:7 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Diagnostic Techniques, Surgical; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Taxoids; Topotecan	2014
Statistical Perspectives on Subgroup Analysis: Testing for Heterogeneity and Evaluating Error Rate for the Complementary Subgroup. Journal of biopharmaceutical statistics, 2015, Volume: 25, Issue:6 Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents; Aspirin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Doxorubicin; Female; Humans; Ischemia; Ovarian Neoplasms; Platelet Aggregation Inhibitors; Reproducibility of Results; Research Design; Sample Size; Ticlopidine; Topotecan	2015
The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience. Taiwanese journal of obstetrics & gynecology, 2015, Volume: 54, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Taiwan; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2015
Thermosensitive, near-infrared-labeled nanoparticles for topotecan delivery to tumors. Molecular pharmaceutics, 2015, May-04, Volume: 12, Issue:5 Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Female; Liposomes; Mice; Microscopy, Fluorescence; Nanomedicine; Nanoparticles; Ovarian Neoplasms; Polyethylene Glycols; Topotecan	2015
Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells. BMC cancer, 2015, Mar-28, Volume: 15 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzodiazepinones; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cisplatin; DNA Damage; DNA Repair; Drug Synergism; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protein Kinases; Pyrazoles; Topoisomerase I Inhibitors; Topotecan	2015
Clinical observational study of conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent ovarian cancer. Genetics and molecular research : GMR, 2015, Apr-22, Volume: 14, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Topotecan; Treatment Outcome	2015
Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer. Drug development and industrial pharmacy, 2016, Volume: 42, Issue:1 Topics: Animals; Antineoplastic Agents, Phytogenic; Blood Cells; Calorimetry, Differential Scanning; Cell Line, Tumor; Drug Combinations; Drug Liberation; Drug Synergism; Female; Folic Acid; Humans; Liposomes; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topoisomerase I Inhibitors; Topotecan	2016
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Gynecologic oncology, 2015, Volume: 139, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Radiography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids; Topotecan; Young Adult	2015
[Nogitecan Hydrochloride Treatment for Patients with Recurrent Ovarian Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Recurrence; Tomography, X-Ray Computed; Topoisomerase Inhibitors; Topotecan; Treatment Outcome	2015
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker. PloS one, 2015, Volume: 10, Issue:8 Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan	2015
Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2015, Volume: 74 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Colorectal Neoplasms; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Glycosylation; Humans; Ovarian Neoplasms; Paclitaxel; Phenotype; Topotecan; Tunicamycin	2015
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. Gynecologic oncology, 2015, Volume: 139, Issue:2 Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan	2015
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Molecular cancer therapeutics, 2015, Volume: 14, Issue:12 Topics: Administration, Metronomic; Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays	2015
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecologic oncology, 2016, Volume: 140, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult	2016
Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer. Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Topotecan	2016
Analysis of two topotecan treatment schedules in patients with recurrent ovarian cancer. Journal of chemotherapy (Florence, Italy), 2016, Volume: 28, Issue:2 Topics: Adult; Aged; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan	2016
Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts. Molecular cancer therapeutics, 2016, Volume: 15, Issue:12 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mice; Ovarian Neoplasms; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays	2016
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecologic oncology, 2008, Volume: 110, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Topotecan	2008
Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-20, Volume: 27, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure	2009
MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecologic oncology, 2009, Volume: 113, Issue:2 Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Linear Models; MicroRNAs; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Taxoids; Topotecan	2009
Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Topotecan; Treatment Outcome	2009
Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants. International journal of cancer, 2009, Nov-15, Volume: 125, Issue:10 Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Colonic Neoplasms; Dextrans; Female; Humans; Leukemia, Myeloid; Macrophages; Melanoma; Mice; Mice, Nude; Ovarian Neoplasms; Tissue Distribution; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2009
[Effect of topotecan on expression of aquaporin protein 5 and nuclear factor-kappaB in ovarian cancer SKOV3 cells]. Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:8 Topics: Antineoplastic Agents; Aquaporin 5; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cytoplasm; Dose-Response Relationship, Drug; Female; Humans; I-kappa B Proteins; NF-KappaB Inhibitor alpha; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transcription Factor RelA	2009
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer biology & therapy, 2009, Volume: 8, Issue:16 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Topotecan; Vascular Endothelial Growth Factor A	2009
Chemotherapy: Topotecan or treosulfan--that is the question. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10 Topics: Antineoplastic Agents; Busulfan; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance; Drug Therapy; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Survival Analysis; Time Factors; Topotecan	2009
Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases. The Journal of reproductive medicine, 2009, Volume: 54, Issue:9 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fatigue; Female; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Thalidomide; Topotecan	2009
Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. The journal of obstetrics and gynaecology research, 2010, Volume: 36, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Epithelium; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Topotecan	2010
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Molecular cancer therapeutics, 2010, Volume: 9, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biological Therapy; Cell Death; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indazoles; Kaplan-Meier Estimate; Mice; Models, Biological; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays	2010
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Molecular cancer therapeutics, 2010, Volume: 9, Issue:4 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indazoles; Irinotecan; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays	2010
Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer. Archives of gynecology and obstetrics, 2011, Volume: 283, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate; Topoisomerase I Inhibitors; Topotecan	2011
Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. British journal of cancer, 2010, Aug-24, Volume: 103, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Topotecan	2010
Chemoresistance testing of human ovarian cancer cells and its in vitro model. Toxicology in vitro : an international journal published in association with BIBRA, 2010, Volume: 24, Issue:8 Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan	2010
Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Cancer biology & therapy, 2010, Dec-01, Volume: 10, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Synergism; Enzyme Activation; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Topoisomerase I Inhibitors; Topotecan; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2010
Another confirmation of the inactivity of topotecan in ovarian cancer. Journal of the National Cancer Institute, 2010, Oct-20, Volume: 102, Issue:20 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Female; Humans; International Cooperation; Multicenter Studies as Topic; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Topotecan; Treatment Failure	2010
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:11 Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan	2010
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Topotecan	2011
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma. Gynecologic oncology, 2011, Volume: 122, Issue:1 Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome	2011
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. Gynecologic oncology, 2011, Volume: 122, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan	2011
Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown. Gynecologic oncology, 2011, Volume: 122, Issue:2 Topics: Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	2011
Long-term topotecan therapy in recurrent or persistent ovarian cancer. European journal of gynaecological oncology, 2011, Volume: 32, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Disease Progression; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2011
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic oncology, 2011, Volume: 123, Issue:2 Topics: Adult; Aged; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan	2011
Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells. Anticancer research, 2012, Volume: 32, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Line, Tumor; Chromones; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Morpholines; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Topotecan	2012
A small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells. PloS one, 2012, Volume: 7, Issue:4 Topics: Analysis of Variance; Annexin A5; Antineoplastic Agents; Blotting, Western; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Flow Cytometry; Humans; In Vitro Techniques; Oligopeptides; Ovarian Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Transduction, Genetic	2012
Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. Investigational new drugs, 2013, Volume: 31, Issue:1 Topics: Animals; Cell Line, Tumor; Copper; Drug Stability; Female; Hydrogen-Ion Concentration; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Ovarian Neoplasms; Peritoneal Cavity; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays	2013
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? The oncologist, 2012, Volume: 17, Issue:12 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Creatinine; Deoxycytidine; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Quality of Life; Recurrence; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Taxoids; Thrombosis; Topotecan	2012
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC cancer, 2012, Aug-29, Volume: 12 Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blotting, Western; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, SCID; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays	2012
[Chemotherapy for recurrent ovarian cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Topotecan	2012
[Treatment of recurrent ovarian cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 4 Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Reoperation; Topotecan	2012
Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-15, Volume: 19, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Female; Humans; Liposomes; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Topotecan; Treatment Outcome	2013
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. International journal of cancer, 2002, Jul-01, Volume: 100, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	2002
Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Gemcitabine; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured; Vinblastine; Vinorelbine	2002
The role of topotecan as second-line therapy in patients with recurrent ovarian cancer. European journal of gynaecological oncology, 2002, Volume: 23, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Endometrioid; Cystadenocarcinoma, Papillary; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Topotecan	2002
Topotecan-induced celluitis-like fixed drug eruption. Journal of the European Academy of Dermatology and Venereology : JEADV, 2002, Volume: 16, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cellulitis; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Eruptions; Fatal Outcome; Female; Humans; Hysterectomy; Infusions, Intravenous; Leg Dermatoses; Ovarian Neoplasms; Ovariectomy; Risk Assessment; Topotecan	2002
Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer, 2002, Oct-15, Volume: 95, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome	2002
A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Blood Transfusion; Cost-Benefit Analysis; Decision Making; Doxorubicin; Drug Costs; Female; Health Care Costs; Health Policy; Hospitalization; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Topotecan; United Kingdom; United States	2002
Modeling plasma and saliva topotecan concentration time course using a population approach. Oncology research, 2003, Volume: 13, Issue:4 Topics: Adult; Aged; Female; Humans; Middle Aged; Models, Biological; Nonlinear Dynamics; Ovarian Neoplasms; Saliva; Time Factors; Topotecan	2003
Second-line chemotherapy for ovarian cancer. The Lancet. Oncology, 2003, Volume: 4, Issue:6 Topics: Antineoplastic Agents; Doxorubicin; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Topotecan	2003
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. The journal of obstetrics and gynaecology research, 2003, Volume: 29, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure	2003
Prolonged stabilization of platinum/paclitaxel-refractory ovarian cancer with topotecan: a case report and review of the literature. Clinical and experimental obstetrics & gynecology, 2003, Volume: 30, Issue:2-3 Topics: Adenocarcinoma, Papillary; Agranulocytosis; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Quality of Life; Topotecan	2003
Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy. Clinical therapeutics, 2003, Volume: 25, Issue:6 Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Doxorubicin; Female; Health Care Costs; Humans; Infusions, Intravenous; Italy; Liposomes; Ovarian Neoplasms; Polyethylene Glycols; Randomized Controlled Trials as Topic; Topotecan	2003
Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. British journal of cancer, 2003, Sep-15, Volume: 89, Issue:6 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Doxorubicin; Drug Costs; Economics, Pharmaceutical; Female; Health Care Costs; Humans; Infusions, Intravenous; Liposomes; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Salvage Therapy; Spain; Topotecan	2003
Apoptotic pathways of epothilone BMS 310705. Gynecologic oncology, 2003, Volume: 91, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cytochrome c Group; Drug Resistance, Neoplasm; Enzyme Activation; Epothilones; Female; Humans; Irinotecan; Isoenzymes; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured	2003
[Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells]. Ai zheng = Aizheng = Chinese journal of cancer, 2003, Volume: 22, Issue:12 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Neoplasm Proteins; Oligonucleotides, Antisense; Ovarian Neoplasms; RNA, Messenger; Topotecan; Transfection; Tumor Cells, Cultured	2003
[Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer]. Ai zheng = Aizheng = Chinese journal of cancer, 2003, Volume: 22, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Middle Aged; Ovarian Neoplasms; Topotecan	2003
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. The American journal of medicine, 2004, Jan-01, Volume: 116, Issue:1 Topics: Anemia; Antineoplastic Agents; Confidence Intervals; Cost Savings; Cross-Cultural Comparison; Drug Utilization; Erythropoietin; Fee-for-Service Plans; Female; Health Expenditures; Hemoglobinometry; Humans; Male; Managed Care Programs; Medical Oncology; Neoplasms; Odds Ratio; Ovarian Neoplasms; Practice Guidelines as Topic; Practice Patterns, Physicians'; Regression Analysis; Topotecan; United States	2004
Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment. Gynecologic oncology, 2004, Volume: 92, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Doxorubicin; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Quality of Life; Topotecan	2004
Recurrent ovarian cancer. Onkologie, 2004, Volume: 27, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure	2004
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. Gynecologic oncology, 2004, Volume: 93, Issue:1 Topics: Adolescent; Adult; Aged; Deoxycytidine; Drug Costs; Drug Resistance, Neoplasm; Female; Gemcitabine; Health Care Costs; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Topotecan	2004
Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach. Cancer research, 2004, Apr-15, Volume: 64, Issue:8 Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Computer Simulation; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Flow Cytometry; G1 Phase; Humans; Mitosis; Models, Biological; Ovarian Neoplasms; S Phase; Topotecan	2004
[The mechanism of topotecan resistance in ovarian cancer cell line]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:3 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Ovarian Neoplasms; RNA, Messenger; Topotecan	2004
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecologic oncology, 2004, Volume: 93, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Topotecan	2004
The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecologic oncology, 2004, Volume: 94, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Genes, MDR; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Topotecan	2004
Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecologic oncology, 2004, Volume: 94, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carboplatin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Caspases; Cell Line, Tumor; Chondrocytes; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Endothelium, Vascular; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Osteoprotegerin; Ovarian Neoplasms; Paclitaxel; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Tumor Necrosis Factor-alpha	2004
Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum? Gynecologic oncology, 2004, Volume: 94, Issue:2 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prognosis; Retrospective Studies; Topotecan	2004
Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation? Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9 Topics: Antineoplastic Agents; Female; Follow-Up Studies; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Time Factors; Topotecan; Treatment Outcome	2004
Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. The Journal of biological chemistry, 2004, Dec-24, Volume: 279, Issue:52 Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cisplatin; Colonic Neoplasms; Cytarabine; DNA; DNA Adducts; DNA Topoisomerases, Type I; Drug Synergism; Enzyme Inhibitors; Female; Humans; Models, Molecular; Ovarian Neoplasms; Platinum Compounds; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	2004
Heterogeneous cell response to topotecan in a CFSE-based proliferation test. Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2004, Volume: 62, Issue:2 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Evaluation Studies as Topic; Female; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Fluorometry; Humans; Ovarian Neoplasms; Succinimides; Time Factors; Topotecan	2004
Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecologic oncology, 2004, Volume: 95, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Topotecan	2004
Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-01, Volume: 10, Issue:23 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Computer Simulation; Cyclohexanes; Dacarbazine; Female; Humans; Male; Models, Biological; O-(Chloroacetylcarbamoyl)fumagillol; Ovarian Neoplasms; Predictive Value of Tests; Rats; Rats, Inbred F344; Rats, Nude; Sesquiterpenes; Temozolomide; Topotecan; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2004
The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence Guidance 2001: the Nottingham experience. Clinical oncology (Royal College of Radiologists (Great Britain)), 2004, Volume: 16, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Medical Audit; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome	2004
[Status report on the chemotherapy of ovarian cancer at special cancer centers in Hungary (2002-2003)]. Magyar onkologia, 2004, Volume: 48, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Docetaxel; Doxorubicin; Female; Humans; Hungary; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Retrospective Studies; Taxoids; Topotecan; Treatment Outcome	2004
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecologic oncology, 2005, Volume: 96, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Topotecan; Xenograft Model Antitumor Assays	2005
Topotecan induced nail pigmentation. The Journal of dermatology, 2004, Volume: 31, Issue:11 Topics: Aged; Antineoplastic Agents; Carcinoma, Papillary; Female; Follow-Up Studies; Humans; Hyperpigmentation; Nail Diseases; Ovarian Neoplasms; Topotecan	2004
CA125 Nadir values as a prognostic factor in epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Prognosis; Topotecan	2005
Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer biology & therapy, 2005, Volume: 4, Issue:6 Topics: Administration, Oral; Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Carcinoma, Small Cell; DNA, Neoplasm; Female; Gene Frequency; Genotype; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Ovarian Neoplasms; Pharmacogenetics; Pilot Projects; Polymorphism, Single Nucleotide; Prospective Studies; Topotecan; Tumor Cells, Cultured	2005
Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecologic oncology, 2005, Volume: 98, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Topotecan	2005
Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecologic oncology, 2005, Volume: 98, Issue:3 Topics: Cisplatin; Cyclophosphamide; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Neoplasm Metastasis; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Topotecan	2005
Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Patient Participation; Patient Selection; Prospective Studies; Retrospective Studies; Topotecan	2005
p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma. Oncology, 2005, Volume: 69, Issue:2 Topics: Aged; Antineoplastic Agents; Carcinoma; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; Topotecan; Treatment Outcome	2005
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy. Gynecologic oncology, 2006, Volume: 100, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Complementary Therapies; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Genistein; Glucuronides; Humans; Isoflavones; Middle Aged; Ovarian Neoplasms; Paclitaxel; Soy Milk; Topotecan	2006
Topotecan in platinum-resistant epithelial ovarian cancer. Chemotherapy, 2005, Volume: 51, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies; Survival Rate; Topotecan; Turkey	2005
Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity. The oncologist, 2005, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Bone Marrow; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Ovarian Neoplasms; Topotecan	2005
Topotecan: weighing in when there are many options. The oncologist, 2005, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Palliative Care; Topotecan	2005
Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chronic Disease; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Secondary Prevention; Topotecan	2005
Comparison of efficacy and toxicity profile between intraperitoneal and intravenous topotecan in human ovarian cancer xenografts. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2006, Feb-18, Volume: 38, Issue:1 Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Omentum; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan; Xenograft Model Antitumor Assays	2006
Altered phosphorylation of topoisomerase I following overexpression in an ovarian cancer cell line. Biochemistry and cell biology = Biochimie et biologie cellulaire, 2006, Volume: 84, Issue:1 Topics: Adenoviridae; Cell Death; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Gene Expression; Humans; Nucleic Acid Conformation; Ovarian Neoplasms; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Transport; Recombinant Fusion Proteins; Topotecan; Tumor Cells, Cultured	2006
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecologic oncology, 2006, Volume: 103, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Retrospective Studies; Topotecan	2006
The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2005, Volume: 46, Issue:4 Topics: CA-125 Antigen; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Topotecan; Treatment Outcome	2005
Is it time for some new approaches for treating advanced ovarian cancer? Journal of the National Cancer Institute, 2006, Aug-02, Volume: 98, Issue:15 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Failure	2006
Cerebral and parotid metachronous metastases from an ovarian carcinoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:11 Topics: Adenocarcinoma, Mucinous; Anticonvulsants; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Parotid Neoplasms; Supratentorial Neoplasms; Topotecan	2006
Topotecan as a second-line therapy in patients with ovarian and primary peritoneal cancer: initial response and long-term follow-up. European journal of gynaecological oncology, 2006, Volume: 27, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Second-Look Surgery; Survival Analysis; Topotecan	2006
Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC cancer, 2007, Apr-15, Volume: 7 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Colostomy; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Epoetin Alfa; Erythropoietin; Fatal Outcome; Female; Follow-Up Studies; Hemorrhage; Humans; Intestinal Obstruction; Karnofsky Performance Status; Laparotomy; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Peritoneal Neoplasms; Recombinant Proteins; Salvage Therapy; Topotecan; Urinary Bladder Neoplasms; Vitamins	2007
Phenoxodiol-Topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects. Cancer biology & therapy, 2007, Volume: 6, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Female; Humans; Isoflavones; Male; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Topotecan; Xenograft Model Antitumor Assays	2007
Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma. Journal of cancer research and clinical oncology, 2007, Volume: 133, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Doxorubicin; Female; Humans; Markov Chains; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Topotecan	2007
Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2007, Volume: 13, Issue:1 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Mice; Mice, Nude; Ovarian Neoplasms; Platinum Compounds; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays	2007
Developmental chemotherapy and management of recurrent ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10 Suppl Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2003
Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecologic oncology, 2008, Volume: 108, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Topotecan	2008
[Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer]. Orvosi hetilap, 2007, Dec-09, Volume: 148, Issue:49 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan; Treatment Outcome	2007
Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC genomics, 2008, Feb-26, Volume: 9 Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Gene Regulatory Networks; Humans; Ovarian Neoplasms; Paclitaxel; Spheroids, Cellular; Topotecan	2008
Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy. Oncology, 2007, Volume: 73, Issue:3-4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Retrospective Studies; Survival Rate; Topotecan; Treatment Outcome	2007
Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. British journal of cancer, 1995, Volume: 71, Issue:3 Topics: Animals; Antineoplastic Agents; Biotransformation; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance; Female; Humans; Injections, Intraperitoneal; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Topotecan; Transplantation, Heterologous	1995
FDA approve bark-derived drug. Lancet (London, England), 1996, Jun-08, Volume: 347, Issue:9015 Topics: Antineoplastic Agents; Camptothecin; Drug Approval; Female; Humans; Ovarian Neoplasms; Topotecan; United States; United States Food and Drug Administration	1996
[Ovarian cancer. The new chemotherapeutic agents]. Soins; la revue de reference infirmiere, 1995, Issue:599 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Topotecan	1995
Trial of topotecan as first-line treatment for ovarian cancer announced. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Topotecan	1996
Topotecan approved for cancer chemotherapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Aug-01, Volume: 53, Issue:15 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Topotecan	1996
Topotecan hydrochloride for metastatic ovarian cancer. The Medical letter on drugs and therapeutics, 1996, Oct-25, Volume: 38, Issue:986 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Ovarian Neoplasms; Topotecan	1996
Hycamtin achieves promising results in study of patients with leukemia. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Ovarian Neoplasms; Remission Induction; Topotecan	1996
Second-line therapy. Nursing standard (Royal College of Nursing (Great Britain) : 1987), 1997, Feb-12, Volume: 11, Issue:21 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan; Treatment Failure	1997
Topotecan: an important new drug in the management of ovarian cancer. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Female; Humans; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
Treatment of recurrent ovarian cancer: increasing options--"recurrent" results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	1997
Clostridium difficile diarrhoea associated with chemotherapy for ovarian cancer. The Australian & New Zealand journal of obstetrics & gynaecology, 1997, Volume: 37, Issue:3 Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clostridioides difficile; Combined Modality Therapy; Enterocolitis, Pseudomembranous; Female; Humans; Middle Aged; Ovarian Neoplasms; Topotecan	1997
Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan. Gynecologic oncology, 1997, Volume: 67, Issue:3 Topics: Bone Marrow; Female; Humans; Kidney Diseases; Ovarian Neoplasms; Topotecan	1997
[Derivatives of camptothecin. A new class of antineoplastic agents]. Soins; la revue de reference infirmiere, 1997, Issue:621 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Ovarian Neoplasms; Topotecan	1997
Correspondence Re: C. Caserini et al., Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies. Clin. Cancer Res., 3: 955-961, 1997. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Enzyme Inhibitors; Female; Humans; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1998
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	1998
Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan. Gynecologic oncology, 1998, Volume: 69, Issue:2 Topics: Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platelet Count; Thrombocytopenia; Topotecan	1998
Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan. Gynecologic oncology, 1998, Volume: 69, Issue:2 Topics: Antineoplastic Agents; Autoantibodies; Carcinoma; Female; Humans; Immunoelectrophoresis; Neoplasm Recurrence, Local; Neurons; Ovarian Neoplasms; Thrombocytopenia; Topotecan	1998
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. British journal of cancer, 1998, Volume: 77, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Line; Cross Reactions; Drug Resistance; Enzyme Inhibitors; Female; Glucose; Humans; Irinotecan; Kinetics; Ovarian Neoplasms; Temperature; Topoisomerase I Inhibitors; Topotecan	1998
Secondary response of ovarian tumors to topotecan treatment. Gynecologic oncology, 1998, Volume: 69, Issue:3 Topics: Adult; Antineoplastic Agents; Female; Humans; Middle Aged; Ovarian Neoplasms; Retreatment; Topotecan; Treatment Outcome	1998
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. British journal of cancer, 1998, Volume: 78, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, p53; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53	1998
O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. Anti-cancer drugs, 1998, Volume: 9, Issue:7 Topics: Antineoplastic Agents; Female; Glucuronates; Humans; Ovarian Neoplasms; Topotecan	1998
Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies. Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:6 Topics: Animals; Apoptosis; Cell Survival; Cisplatin; Clone Cells; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Exons; Female; Genes, p53; Humans; Mice; Mice, Nude; Mutation; Ovarian Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	1997
Back to the future: multiagent chemotherapy in ovarian cancer revisited. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Female; Humans; Laparotomy; Ovarian Neoplasms; Paclitaxel; Topotecan	1999
Topotecan: new preparation. No proven benefit. Prescrire international, 1998, Volume: 7, Issue:34 Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Female; France; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Outcome	1998
Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line. Anti-cancer drugs, 1999, Volume: 10, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Division; DNA Damage; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Female; Half-Life; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1999
Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. International journal of oncology, 1999, Volume: 15, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Survival Analysis; Survival Rate; Time Factors; Topotecan; Treatment Outcome	1999
Adaptation of solid phase extraction to an automated column switching method for online sample cleanup as the basis of a facile and sensitive high-performance liquid chromatographic assay for paclitaxel in human plasma. Journal of pharmaceutical and biomedical analysis, 1999, Volume: 21, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Doxorubicin; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Paclitaxel; Reproducibility of Results; Topotecan	1999
Modern treatment of ovarian cancer. Scottish medical journal, 2000, Volume: 45, Issue:2 Topics: Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan	2000
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Temozolomide; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay	2000
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	2000
P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. Cancer research, 2001, Feb-01, Volume: 61, Issue:3 Topics: Cell Division; Cisplatin; Clone Cells; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Nuclear Proteins; Ovarian Neoplasms; RNA, Messenger; Topotecan; Transfection; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Ultraviolet Rays	2001
Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:1 Topics: Antineoplastic Agents; Female; Humans; Middle Aged; Ovarian Neoplasms; Renal Dialysis; Renal Insufficiency; Topotecan	2001
Clear cell carcinoma of the ovary: a remarkable case. American journal of clinical oncology, 2001, Volume: 24, Issue:1 Topics: Adenocarcinoma, Clear Cell; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cisplatin; Etoposide; Female; Humans; Ovarian Neoplasms; Quality of Life; Topotecan	2001
Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. Japanese journal of clinical oncology, 2001, Volume: 31, Issue:2 Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prospective Studies; Topotecan	2001
Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer research, 2001, May-15, Volume: 61, Issue:10 Topics: Amino Acid Sequence; Azacitidine; Base Sequence; Chromosome Mapping; Cisplatin; Cloning, Molecular; Decitabine; DNA, Neoplasm; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; In Situ Hybridization, Fluorescence; Loss of Heterozygosity; Molecular Sequence Data; Ovarian Neoplasms; Oximes; Paclitaxel; Piperazines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Topotecan; Transfection; Tumor Cells, Cultured	2001
[The effect of hydroxycamptothecin and topotecan to SKOV3 and CAOV3 in vitro]. Zhonghua fu chan ke za zhi, 1999, Volume: 34, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured	1999
Topotecan and PML: the limits of pharmaceutical industry research. Notes from the underground (New York, N.Y.), 1996, Issue:No 33 Topics: AIDS-Related Opportunistic Infections; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Consumer Advocacy; Drug Approval; Drug Evaluation, Preclinical; Drug Industry; Health Services Accessibility; HIV Infections; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Ovarian Neoplasms; Topotecan	1996
Clonal heterogeneity of p53 mutations in ovarian cancer. International journal of oncology, 2001, Volume: 19, Issue:2 Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Cisplatin; Clone Cells; DNA Mutational Analysis; DNA, Neoplasm; Female; Genetic Heterogeneity; Humans; Immunoblotting; Lethal Dose 50; Mutation; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single-Stranded Conformational; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2001
Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:10 Topics: Animals; Antineoplastic Agents; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Time Factors; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Tumor Cells, Cultured; Weight Loss; Xenograft Model Antitumor Assays	2001
Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecologic oncology, 2001, Volume: 83, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Topotecan	2001
Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells. Oncology research, 2000, Volume: 12, Issue:9-10 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Flow Cytometry; Gemcitabine; Humans; Inhibitory Concentration 50; Ovarian Neoplasms; Time Factors; Topotecan; Tumor Cells, Cultured; Tumor Protein, Translationally-Controlled 1	2000
Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer. European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:18 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Saliva; Topotecan	2001
The use of oral cytotoxic and cytostatic drugs in cancer treatment. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:1 Topics: Administration, Oral; Antineoplastic Agents; Biological Transport; Drug Interactions; Female; Humans; Intestinal Absorption; Intestines; Ovarian Neoplasms; Patient Compliance; Topotecan	2002
[Single topotecan or in combination with other chemotherapeutic agents for 18 recurrent advanced ovarian cancer patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2001, Volume: 23, Issue:6 Topics: Adult; Antineoplastic Agents; Female; Humans; Middle Aged; Ovarian Neoplasms; Recurrence; Topotecan; Treatment Outcome	2001
Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study. Anti-cancer drugs, 2002, Volume: 13, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; DNA Topoisomerases, Type I; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocytes; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured	2002
Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer, 2002, Apr-01, Volume: 94, Issue:7 Topics: Age Factors; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Topotecan	2002
Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer. Cancer gene therapy, 2002, Volume: 9, Issue:5 Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Female; Genetic Therapy; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Treatment Outcome; Tumor Cells, Cultured	2002
Recurrent ovarian cancer as chronic disease. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chronic Disease; Deoxycytidine; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Recurrence; Topotecan; Trastuzumab	2002
Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. British journal of cancer, 2002, May-20, Volume: 86, Issue:10 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Stability; Female; Glucuronides; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Prodrugs; Sex Factors; Solubility; Topotecan; Tumor Cells, Cultured; Weight Loss; Xenograft Model Antitumor Assays	2002